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ABSTRACT
1
 
 Cytochrome c oxidase (COX) is a multimeric protein complex embedded in the inner 
mitochondrial membrane that contributes to the electrochemical potential ultimately required for 
adenosine triphosphate (ATP) synthesis.  Synthesis of Cytochrome c Oxidase 1 (SCO1) and 
SCO2 are two of many accessory proteins that facilitate the assembly of individual COX 
structural subunits into a functional holoenzyme complex.  SCO1 and SCO2 also function to 
regulate cellular copper homeostasis.  Both of these functions require that SCO proteins 
collaborate with several interacting partners. With few exceptions, however, their protein 
partners have yet to be identified and, as a consequence, we lack mechanistic insight into SCO 
protein function.  To address this gap in our knowledge, I used physical methods to identify 
interacting partners of SCO1.  Physical interactions between potential interacting partners of 
endogenous SCO1 or overexpressed SCO1-FLAG were stabilized with a chemical crosslinker, 
and the protein complexes were purified using the appropriate primary antibody.  Mass 
spectrometric analysis of the eluates provided two lists of potential interacting partners that were 
subsequently filtered by gene ontology function and mitochondrial localization.  The final list 
was comprised of 85 proteins, which were rank ordered based on total peptide counts per protein.  
Three of these candidate interacting partners were then further characterized; COX20, 
tricarboxylate transport protein (SLC25A1) and mitochondrial 2-oxoglutarate/malate carrier 
(SLC25A11).  I first confirmed the authenticity of the observed interactions by conducting the 
reciprocal co-immunoprecipitations in the absence of a chemical crosslinker.  I then investigated 
the effect of transient knockdown of each protein on the abundance of COX II, a direct proxy of 
total COX content.  Knockdown of COX20 and SLC25A1 reduced COX II levels in SCO1 and 
SCO2 patient fibroblasts, but did not affect COX II abundance in control cells.  SLC25A11 
knockdown lowered COX II abundance in both control and SCO patient cells.  These data 
suggest that the ability of SCO1 to interact with each of these proteins somehow facilitates the 
maturation of the CuA site of COX II.   
 
                                               
1 Throughout my thesis, I use capitalized text when referring to a human protein (e.g. SCO1), and italicized, 
capitalized text when referring to a human gene (e.g. SCO1). Yeast proteins and genes are distinguished from their 
human counterparts by the use of a single capital letter at the beginning of the text in question (e.g. Sco1 or Sco1). 
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1 INTRODUCTION 
1.1 Mitochondria 
Mitochondria are eukaryotic organelles that are generally described as “power plants”, 
because they generate the majority of the adenosine triphosphate (ATP) that is ultimately 
consumed by various cellular processes (McBride et al., 2006).  In addition to their role in 
energy production, mitochondria are involved in cell signaling, differentiation, apoptosis, and 
cell cycle control (Horn and Barrientos, 2008; McBride et al., 2006; Pierrel et al., 2007).  
Mitochondrial dysfunction is thought to play a significant role in aging, and is known to cause 
early and late onset diseases that affect almost every organ system of the human body 
(Kazachkova et al., 2013; Zsurka and Kunz, 2013).  The ability to maintain a functional 
population of mitochondria is therefore essential for the health of a eukaryotic cell.   
Mitochondria are thought to have originated from a formerly free-living aerobic 
proteobacterium that was taken up by a larger host cell.  Over evolutionary time, the 
proteobacterium genome has been reduced in size by lateral transfer of the majority of its genes 
to the host nucleus (Gray et al., 1999).  However, the mitochondrion of all eukaryotic cells has 
retained a multi-copy genome that is small, circular and encodes a number of genes critical to 
ATP production.  Organelle biogenesis therefore requires the coordinate expression of nuclear- 
and mitochondrially-encoded genes (Anderson et al., 1981; Ott and Herrmann, 2010; Sickmann 
et al., 2003).  The number of mitochondria present in unicellular organisms or in tissues of 
multicellular organisms varies considerably, with cells having anywhere from one to hundreds of 
mitochondria (Fernandez-Vizarra et al., 2011).   
 
1.1.1 Mitochondrial structure  
Mitochondria are made up of two membranes that separate the organelle into four distinct 
compartments; the outer mitochondrial membrane (OMM), the intermembrane space (IMS), the 
inner mitochondrial membrane (IMM) and the matrix.  The IMS is located between the OMM 
and IMM, while the matrix is enclosed within the IMM.   
 The OMM is semi-permeable, which allows ions and small molecules to move by passive 
diffusion through transmembrane channel proteins called porins or through the translocase of the 
outer mitochondrial membrane called the TOM complex (Colombini, 1979; Freitag et al., 1982; 
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Zalman et al., 1980).  The TOM complex, which is a large, multi-protein molecular motor, also 
functions to import proteins into the organelle, by recognizing the mitochondrial targeting 
sequences of nuclear-encoded proteins that are translated on cytosolic ribosomes (Neupert and 
Herrmann, 2007).   
 Unlike the OMM, the IMM is impermeable and active transport mechanisms are required 
to move ions, small molecules and proteins across this lipid bilayer (Endo et al., 2011; Neupert 
and Herrmann, 2007).  The translocase of the inner mitochondrial membrane (TIM) complex 
recognizes the mitochondrial targeting sequence on proteins to facilitate transport across the 
IMM (Neupert and Herrmann, 2007).  While the impermeable nature of the IMM poses a 
challenge for protein and metabolite transport, it is a feature that is essential for aerobic ATP 
production.  Five multimeric enzyme complexes integral to the IMM function to produce ATP in 
a process known as oxidative phosphorylation.  The first four complexes form the respiratory 
chain and pump protons across the IMM into the IMS, to generate an electrochemical gradient 
that is then used by Complex V to synthesize ATP (Figure 1.1).  Mitochondria of cells and 
organisms that rely heavily on oxidative phosphorylation tend to have a highly invaginated IMM, 
which leads to the formation of structures called cristae.  Cristae effectively increase the total 
surface area of the IMM and allow for higher concentrations of these five complexes to increase 
energy production (Schultz and Chan, 2001). 
The IMS is located between the OMM and IMM.  This aqueous environment is more 
oxidizing and has a lower pH than either the cytosol or the mitochondrial matrix, properties that 
are attributable at least in part to the proton gradient generated by the respiratory chain 
(Herrmann and Hell, 2005; Hu et al., 2008).  The matrix is completely enclosed by the IMM, and 
contains the multi-copy mitochondrial genome, along with transcriptional and translational 
machinery that is required for its expression.  This compartment also houses enzymes of the 
citric acid cycle and those required for fatty acid oxidation.  Lastly, the matrix contains labile 
pools of iron, copper, zinc, and manganese ions required to metallate and mature specific 
mitochondrial proteins (Pierrel et al., 2007; Rhee et al., 2013). 
 
1.1.2 Protein import into mitochondria 
 Mitochondria are unique among cellular organelles in that their biogenesis requires the 
coordinate expression of the nuclear and mitochondrial genomes.  Because the overwhelming 
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majority of mitochondrial proteins are nuclear-encoded, mitochondria have evolved highly 
sophisticated, multi-protein assemblies to mediate protein import into the organelle, and to 
facilitate sorting of these proteins to distinct mitochondrial compartments (Becker et al., 2012; 
Neupert and Herrmann, 2007).  All imported proteins are first recognized by subunits of the 
TOM complex and then transported through the OMM (Endo et al., 2011).  Recognition by the 
TOM complex is contingent upon a mitochondrial targeting sequence (Endo and Kohda, 2002; 
Mossmann et al., 2012); however, nuclear-encoded mitochondrial proteins exhibit tremendous 
variability with respect to their targeting sequences and whether or not they are cleaved during 
protein import or their subsequent maturation (Endo et al., 2011; Neupert and Herrmann, 2007).   
 
 
Figure 1.1: Schematic of aerobic respiration.  Four multimeric protein complexes (I through IV) 
form the electron transport chain, which functions to pump protons across the IMM from the 
matrix to the IMS.  The resultant electrochemical gradient is then used by Complex V to produce 
ATP.  The black lines represent the movement of electrons between the protein complexes.  The 
red arrows denote the protons pumped through various protein complexes into the IMS.  
Complexes I and II shuttle electrons from nicotinamide adenine dinucleotide (NADH) and 
succinate, respectively, to coenzyme Q (Q).  Complex III catalyzes the transfer of electrons from 
coenzyme Q to cytochrome c.  The final complex in the electron transport chain, Complex IV, 
uses electrons from cytochrome c to reduce oxygen to water (Redrawn from Schultz and Chan, 
2001). 
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 After their translocation through the TOM complex, precursor proteins are recognized by 
specific sorting pathways and trafficked to distinct mitochondrial compartments (Figure 1.2).  
Proteins bound by TIM23 (the presequence translocase of the inner mitochondrial membrane) 
are destined for the matrix or the IMM, if they interact with OXA1 (Oxidase assembly mutant 1) 
(Hell et al., 1998; Neupert and Herrmann, 2007).  The TIM22 (the carrier translocase of the inner 
mitochondrial membrane) complex also recognizes proteins targeted to the IMM.  The SAM 
(sorting and assembly machinery) complex interacts with proteins that are resident to the OMM, 
while the MIA (mitochondrial intermembrane space import and assembly) pathway promotes the 
retention of small soluble proteins within the IMS by inducing conformational changes in their 
tertiary structure (Becker et al., 2012; Chacinska et al., 2009; Endo et al., 2011; Koehler and 
Tienson, 2009; Paschen et al., 2005).  I will only present the TIM23 and MIA sorting pathways 
because SCO1, the focus of my M.Sc. thesis research, is integral to the IMM and is known to 
interact with several soluble, cysteine-rich IMS proteins (Banci et al., 2008; Buchwald et al., 
1991; Leary et al., 2004; Leary et al., 2007; Leary et al., 2009; Leary et al., 2013b). 
 
 
Figure 1.2: Pathways by which nuclear-encoded proteins are imported into and sorted within the 
mitochondrion.  The TOM complex acts as the main entry for proteins into the mitochondrion.  
The SAM complex interacts with proteins destined for the OMM, while the MIA pathway uses a 
disulfide relay system to induce conformational changes in target proteins to promote their 
retention within the IMS.  Proteins interacting with the TIM23 complex are targeted to the IMM 
or matrix, while TIM22 chaperones the insertion of proteins into the IMM (Adapted from 
Chacinska et al., 2009).   
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1.1.2.1 The TIM23 pathway 
The TIM23 complex and its associated motor, PAM (presequence translocase-associated 
motor), transport precursor proteins across the IMM (Figure 1.3) (Chacinska et al., 2009; Endo et 
al., 2011).  The TIM23 complex is the most complicated translocase of the mitochondrion, 
because its energy-dependent activity must be coordinated with that of the TOM complex and 
the respiratory chain (Herrmann et al., 2012; Neupert and Herrmann, 2007).   
The core of TIM23 is formed by three essential subunits; Tim50 which has a receptor 
domain in the IMS (Geissler et al., 2002; Mokranjac et al., 2009; Tamura et al., 2009; 
Yamamoto et al., 2002), Tim23 which forms the pore (Alder et al., 2008; Truscott et al., 2001), 
and Tim17 which recruits the motor proteins required for translocation (Chacinska et al., 2005; 
Martinez-Caballero et al., 2007).  Both Tim50 and Tim23 interact with a fourth non-essential 
subunit, Tim21, to facilitate transient interactions with proteins of the TOM complex (Chacinska 
et al., 2005; Meinecke et al., 2006; Mokranjac et al., 2009; Tamura et al., 2009).  This provides a 
route to import proteins directly from the cytosol into the matrix.  Tim21 also facilitates 
interactions between  the  TIM23  complex  and  Complexes III and IV of the respiratory chain, 
and therefore supports protein import that is dependent on a membrane potential (Dienhart and 
 
 
Figure 1.3: The components of the TIM23 and PAM complexes.  The TIM23 complex forms the 
protein-conducting pore (green) while the PAM complex (red) acts as the import motor.  TIM23 
is made up of three essential subunits (Tim50, Tim17, and Tim23) as well as the non-essential 
Tim21.  The central component of the PAM complex is mtHSP70.  Several other regulatory 
factors are essential to its function (Pam18, Pam16, Pam44, Mge1), while Pam17 function is 
dispensable  (Redrawn from Chacinska et al., 2009). 
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Stuart, 2008; van der Laan et al., 2006; Wiedemann et al., 2007).  The transport and processing 
of precursor proteins across the IMM also depends on the coordinated and cooperative functions 
of the TIM23 and PAM complexes.  Membrane potential is required to open the Tim23 pore, and 
supports transport of a positively charged mitochondrial targeting sequence into the negatively 
charged matrix (Meinecke et al., 2006; Shariff et al., 2004).  Once a protein is contained within 
the TIM23 complex, the matrix localized PAM motor complex is required for active protein 
transport (Neupert and Herrmann, 2007).  The central subunit of the PAM complex is the 
mitochondrial heat shock protein 70 (mtHsp70) which hydrolyzes ATP to drive the translocation 
of the polypeptide chain (Chacinska et al., 2009).  The PAM complex consists of three more 
essential subunits; Mge1 which promotes the release of ADP to allow for another round of ATP 
binding (Schneider et al., 1996), Pam18 which stimulates the ATPase activity (Li et al., 2004), 
Pam16 which regulates Pam18 (Kozany et al., 2004; Li et al., 2004; Mokranjac et al., 2006), and 
Tim44 which provides mtHsp70 with a binding site close to the channel (Krayl et al., 2007; 
Slutsky-Leiderman et al., 2007).  Pam17 is not essential but promotes interactions between the 
TIM23 and PAM complexes, and is released prior to protein translocation (Hutu et al., 2008; 
Popov-Celeketic et al., 2008).  Several proteins are initially translocated into the matrix by the 
TIM23 complex prior to being exported for their integration into the IMM (Baumann et al., 
2002; Herrmann et al., 1997).  Although Oxa1 fulfills a critical role in matrix export of these 
proteins into the IMM, the mechanisms generally remain ill-defined (Hell et al., 1998; Neupert 
and Herrmann, 2007).   
 
1.1.2.2 The MIA pathway 
 The MIA pathway recognizes soluble proteins that contain twin CxxxC or Cx9C motifs 
and relies on a disulphide relay system to import members of this mitochondrial protein family 
into the IMS (Chacinska et al., 2009).  After being translocated through the TOM complex, the 
cysteines of these highly conserved motifs are oxidized to form an intramolecular disulfide bond.  
Their oxidation results in a transition from a linear disordered polypeptide to one that is folded 
into a helical hairpin, a conformational change that prevents retrotranslocation of the protein into 
the cytosol (Figure 1.4) (Allen et al., 2003; Becker et al., 2012; Herrmann et al., 2012; Lutz et 
al., 2003).   
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The MIA pathway consists of two core proteins; MIA40 and ERV1 (essential for 
respiration and vegetative growth protein 1) (Chacinska et al., 2004; Chacinska et al., 2009; 
Mesecke et al., 2005).  MIA40, in humans, is a soluble IMS protein that uses a conserved 
intramolecular  disulfide  bond  to  oxidize  target  proteins  (Banci et al., 2009; Chacinska et al.,    
 
 
Figure 1.4: Diagram of the MIA pathway.  The MIA pathway utilizes a disulfide relay system to 
oxidize proteins that contain cysteine-rich motifs, thereby forming intramolecular disulfide 
bonds that prevent their retrotranslocation from the IMS.  The MIA pathway consists of two core 
components; MIA40 and ERV1.  MIA40 oxidizes the target twin CxxxC or Cx9C motifs of 
newly imported precursor proteins to drive their oxidative folding.  ERV1 then oxidizes MIA40, 
to re-prime it for a subsequent round of protein import.  Reduced and oxidized thiol groups are 
indicated by SH and S-S, respectively.  (Adapted from Chacinska et al., 2009) 
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2009; Milenkovic et al., 2007). This  process  leaves  MIA40  in  a  reduced  and  inactive  state; 
however, ERV1 can accept electrons from MIA40, which oxidizes and reactivates the protein 
(Mesecke et al., 2005; Rissler et al., 2005).  ERV1 subsequently delivers the electrons to 
cytochrome c for the production of water, a mechanism that couples the activity of the disulfide 
relay system to that of the respiratory chain (Bihlmaier et al., 2007; Dabir et al., 2007).   
 
1.1.3 Translation of mitochondrially-encoded proteins 
 The mammalian mitochondrial genome encodes 13 polypeptides that are part of the 
catalytic core of various complexes of oxidative phosphorylation; ND1-ND6 and ND4L of 
Complex I, cytochrome b of Complex III, COX I-III of Complex IV, and ATP6 and ATP9 of 
Complex V (Anderson et al., 1981; Ott and Herrmann, 2010).  The transcription of these 
mRNAs is unique from that of their nuclear counterparts, because the genome is circular and it 
lacks introns (Clayton, 1982; Graziewicz et al., 2006).  The basic human mitochondrial 
transcriptional machinery is composed of a single RNA polymerase, mitochondrial transcription 
factor A (TFAM) and either mitochondrial transcription factor B1 (TFB1M) or B2 (TFB2M).  
The precise contribution of each of these three factors to transcription remains unknown 
(Falkenberg et al., 2007; Smits et al., 2010).  Transcription originates from one of three 
promoters; HSP1, HSP2, and LSP.  Transcripts from the HSP2 and LSP generate polycistronic 
molecules that contain the majority of messenger RNAs including all those encoding proteins, 
while the HSP1 transcript contains the 12S and 16S ribosomal RNAs (Falkenberg et al., 2007; 
Smits et al., 2010).  Termination of transcription appears to involve three mitochondrial 
transcription termination factors (MTERF); MTERF1, MTERF2, and MTERF3.  However, the 
interplay between these 3 factors and the exact mechanism by which transcription is terminated 
are not yet clear (Smits et al., 2010) Subsequent processing of these polycistronic transcripts 
results in the release of individual mRNAs and the tRNAs necessary for their translation.  The 
translational apparatus consists of mitochondrial ribosomes (mt-ribosomes), mt-tRNA, 
translational activators, and other regulatory factors (Herrmann et al., 2013; Smits et al., 2010).  
The majority of mt-ribosomes are associated with the IMM, to facilitate the co-translational 
insertion of polypeptides into the lipid bilayer.  Membrane insertion is facilitated by a number of 
protein chaperones, including Oxa1 (Hell et al., 2001; Herrmann et al., 2012).  Oxa1 is 
embedded within the IMM, and is thought to bind mt-ribosomes tightly with its C-terminal tail 
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(Jia et al., 2003).  Oxa1 has also been shown to bind to newly synthesized polypeptides, and 
mediates their insertion into the IMM by forming a pore in the membrane (Hell et al., 2001; 
Szyrach et al., 2003).  The function of Oxa1 is supported by Mba1 (multi-copy bypass of AFG3 
(ATPase Family Gene)), which also associates with mt-ribosomes and plays a role in aligning 
the ribosome exit tunnel with the site of protein insertion into the membrane (Preuss et al., 
2002).  However, even in the absence of Mba1 and Oxa1, mt-ribosomes remain partially 
anchored to IMM suggesting there are more factors involved in co-translational insertion of 
mitochondrial polypeptides into the membrane (Ott et al., 2006).   
 
1.1.4 Mitochondrial diseases 
 Mitochondrial diseases are among the most common genetic disorders in humans, with a 
minimum estimated birth prevalence of 1 in 5,000 (Skladal et al., 2003).  More than 150 distinct 
forms of mitochondrial diseases have been reported to date, and are caused by mutations in either 
mitochondrial or nuclear DNA (Vafai and Mootha, 2012).  Mitochondrial DNA (mt-DNA) 
disorders are maternally inherited, as mt-DNA is derived from the oocyte (Holt et al., 1988; 
Vafai and Mootha, 2012; Wallace et al., 1988).  The onset of clinical symptoms tends to be later 
in life, because cells contain multiple copies of mt-DNA and mutated copies of the genome must 
accumulate to a certain threshold to impair organelle function (Vafai and Mootha, 2012).  
Pathogenic mutations in nuclear-encoded mitochondrial genes are far more common, and 
produce a large number of clinically heterogeneous forms of human disease (Schapira, 2012).  
Not surprisingly, the majority of mitochondrial diseases are caused by defects in oxidative 
phosphorylation.  All of the associated complexes, except Complex II, are composed of both 
mitochondrially- and nuclear-encoded structural subunits (Vafai and Mootha, 2012).  The 
assembly of individual structural subunits into functional holoenzymes is complicated, and 
depends on a surprisingly large number of nuclear-encoded accessory proteins termed assembly 
factors.  Mutations in genes encoding these assembly factors therefore affect the assembly and/or 
stability of one or more complexes of oxidative phosphorylation, which in turn severely impairs 
ATP synthesis and energy homeostasis (Ghezzi and Zeviani, 2012; Scaglia, 2012).  Currently, 
over 100 pathogenic mutations have been described in nuclear-encoded genes for mitochondrial 
proteins (Vafai and Mootha, 2012).  Little is understood about the underlying clinical phenotypes 
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of the associated diseases, and the development of effective therapeutic interventions is limited 
by this gap in our knowledge (Schon and DiMauro, 2003). 
 
1.2 Cytochrome c oxidase (COX) 
In eukaryotes, COX or Complex IV is a large multimeric protein complex embedded 
within the IMM.  It is the terminal enzyme of the electron transport chain, and it utilizes 
electrons from cytochrome c to catalyze the conversion of oxygen to water, a reaction that also 
results in the pumping of a proton into the IMS.  This proton pumping contributes to the 
electrochemical gradient required by Complex V for ATP synthesis (Schultz and Chan, 2001). 
 
1.2.1 Structure of COX 
 Mammalian COX is composed of 13 structural subunits (Tsukihara et al., 1996).  Ten of 
these subunits are nuclear-encoded, while three are encoded by the mitochondrial genome (COX 
I – III) and form the catalytic core of the enzyme (Fontanesi et al., 2008).  COX requires two 
heme (a, a3) and two copper (CuA, CuB) prosthetic groups for its catalytic activity along with a 
magnesium ion and zinc ion (Tsukihara et al., 1995; Tsukihara et al., 1996).  Currently, there is 
no information on the mechanism of delivery for the magnesium and zinc ions found in COX.  
Similarly, there is no evidence if their presence has an effect on enzyme function (Cobine et al., 
2006c; Soto et al., 2012).  COX I contains the two heme moieties and a mononuclear copper site, 
CuB.  COX II contains a binuclear multi-valent copper site, CuA (Fontanesi et al., 2008; 
Khalimonchuk and Rodel, 2005).  Electrons are transferred from cytochrome c to the CuA site of 
COX II, and then from heme a to the binuclear heme a3-CuB site where O2 is reduced to water 
(Yoshikawa et al., 2012).  The catalytic core is surrounded by the remaining, nuclear-encoded 
subunits, which stabilize the holoenzyme and provide allosteric sites for the reversible regulation 
of its activity (Stiburek and Zeman, 2010).   
 
1.2.2 COX assembly 
Biogenesis of COX is an ordered, step-wise process that depends on the coordinate 
expression of mitochondrially and nuclear-encoded subunits, and the addition of metal co-factors 
at the appropriate stage of assembly (Cobine et al., 2006c; Stiburek and Zeman, 2010).  
Maturation of the holoenzyme is preceded by the formation of three distinct assembly 
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intermediates (S1-S3).  Progression through the various stages of assembly is a complex process 
involving more than 30 nuclear-encoded accessory proteins termed COX assembly factors 
(Fontanesi et al., 2008).  The majority of these COX assembly factors were initially identified in 
yeast deletion strains that were respiratory-deficient owing to an isolated COX deficiency 
(Tzagoloff and Dieckmann, 1990).  Many of these yeast proteins are highly conserved and have 
human orthologues, even though there are significant differences between both species with 
respect to how the holoenzyme is assembled (Barrientos et al., 2002; Scaglia, 2012; Zee and 
Glerum, 2006). 
 
1.2.2.1 Synthesis and maturation of mitochondrially-encoded COX subunits 
COX I-III form the catalytic core of COX, and are relatively large, hydrophobic proteins 
that are encoded by the mitochondrial genome (Fontanesi et al., 2008; Tsukihara et al., 1996).  
Their individual mRNAs are all translated by mt-ribosomes that are associated with the IMM, 
which allows for co-translational insertion of the proteins into the lipid bilayer (Jia et al., 2003; 
Szyrach et al., 2003).  The expression of these core catalytic subunits is tightly regulated (Figure 
1.5) (Ott and Herrmann, 2010; Zee and Glerum, 2006).  In yeast, several translational activators 
have been shown to bind the 5’ untranslated region of COX I-III mRNAs (Costanzo and Fox, 
1988; Naithani et al., 2003; Sanchirico et al., 1988).  Mss51 (mitochondrial splicing suppressor) 
and Pet309 are two of these activators that promote the synthesis of Cox1 (Manthey and 
McEwen, 1995; Perez-Martinez et al., 2003).  However, Mss51 has also been shown to form a 
complex with Cox1 which is thought to provide a negative feedback loop preventing Mss51 from 
stimulating further translation of Cox1 mRNA (Perez-Martinez et al., 2003).  The Mss51-Cox1 
interaction could also serve to stimulate holoenzyme biogenesis by recruiting other COX 
assembly factors such as Cox14, Cox25, Ssc1, and Mdj1 (Barrientos et al., 2004; Fontanesi et 
al., 2010; Fontanesi et al., 2011; Mick et al., 2010).  Pet111 is integral to the IMM and promotes 
Cox2 synthesis (Mulero and Fox, 1993).  Cox3 translation is activated by a complex composed 
of Pet54, Pet122, and Pet494 (Brown et al., 1994).  Unlike yeast mitochondrial mRNAs, human 
mitochondrial mRNAs do not contain 5’ untranslated regions, and translational activators are 
therefore thought to recognize motifs 3’ of the start codon (Falkenberg et al., 2007; Montoya et 
al., 1981; Scarpulla, 2008).  Mitochondrial mRNAs are polyadenylated which increases stability; 
however, the potential significance of polyadenylation in regulating translation remains poorly 
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understood (Tomecki et al., 2004).  To date, only two mammalian translational activators of 
mitochondrially-encoded COX subunits have been identified, and both participate in the 
translation of COX I mRNA; translational activator of COX I (TACO1) (Weraarpachai et al., 
2009) and Leucine-Rich Pentatricopeptide Repeat Containing protein (LRPPRC) (Mootha et al., 
2002; Sasarman et al., 2010).  LRPPRC also appears, however, to play a general role in the 
stability of mitochondrially-encoded mRNAs (Sasarman et al., 2010), perhaps by facilitating 
their polyadenylation (Ruzzenente et al., 2012)  
 
 
Figure 1.5: The pathway of assembly for mitochondrially-encoded Cox subunits in yeast.  COX 
assembly factors are in rounded rectangles, while COX subunits are in rectangles (Adapted from 
Zee and Glerum, 2006). 
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Several additional accessory proteins collaborate with translational activators to facilitate 
the insertion of newly synthesized Cox1-3 into the IMM and promote subsequent maturation of 
each polypeptide (Figure 1.5) (Ott and Herrmann, 2010; Zee and Glerum, 2006).  The associated 
molecular mechanisms have been most thoroughly investigated and therefore are best understood 
for Cox2.  Fully matured Cox2 is anchored within the IMM by two transmembrane domains, and 
its N- and C-termini both protrude into the IMS (Soto et al., 2012).  Oxa1 catalyzes the export of 
the N-terminal tail of newly-synthesized Cox2 across the IMM, a process that anchors its first 
transmembrane domain within the lipid bilayer (He and Fox, 1997; Hell et al., 1998).  In yeast, 
Cox20 then presents Cox2 to an inner membrane peptidase complex so that its presequence may 
be cleaved, to yield the mature protein (Hell et al., 2000).  The cooperative action of Cox18, 
Mss2, and Pnt1 (PeNTamidine resistance) then catalyzes the anchoring of the second C-terminal 
transmembrane domain of Cox2 in the IMM (Broadley et al., 2001; Fiumera et al., 2007; He and 
Fox, 1999; Saracco and Fox, 2002).   
 
1.2.2.2 Synthesis, delivery and insertion of prosthetic groups during COX assembly  
 Assembly of a catalytically competent enzyme requires that all prosthetic groups are 
added to the relevant structural subunits during the assembly process (Cobine et al., 2006a; 
Cobine et al., 2006c). Much progress has been made with respect to our understanding of how 
these prosthetic groups are synthesized, delivered and inserted into COX I and COX II (Soto et 
al., 2012).  The heme A required to mature COX I is synthesized within the mitochondrion 
(Tsukihara et al., 1995).  Both COX10 and COX15 are required for the synthesis of heme A 
(Glerum and Tzagoloff, 1994; Valnot et al., 2000a; Barros et al., 2001; Barros and Tzagoloff, 
2002).  Yeast Shy1 then catalyzes the insertion of heme A into newly synthesized Cox1 (Mick et 
al., 2007).  Pathogenic mutations in the human orthologue of Shy1, SURF1, cause severe forms 
of disease associated with an isolated COX deficiency (Smith et al., 2005; Zhu et al., 1998).   
While it is now firmly established that a labile copper pool housed in the mitochondrial 
matrix represents the source of copper used to metallate the CuB and CuA sites of COX I and 
COX II, respectively (Cobine et al., 2006a), virtually nothing is known about how that copper is 
transported to the mitochondrion and within the organelle itself.  In fact, the first protein 
involved in copper transport across the IMM, Pic2, was only identified earlier this year (Vest et 
al., 2013), and it is clear that many more proteins are involved in the regulating mitochondrial 
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copper trafficking (Cobine et al., 2006c).  Much more is known, however, about the mechanisms 
that mediate copper delivery to Cox1 and Cox2 within the IMS.  Cox17, a small soluble, 
cysteine-rich metallochaperone within the IMS (Glerum et al., 1996a), binds copper and 
transfers it to the IMM anchored metallochaperones Cox11 (Carr et al., 2002), SCO1 (Glerum et 
al., 1996b), and SCO2 (Banci et al., 2007b; Banci et al., 2008; Horng et al., 2004; Papadopoulou 
et al., 1999).  Studies in bacteria (Hiser et al., 1999) and yeast (Carr et al., 2002) provide 
compelling evidence that Cox11 delivers copper to the CuB site of Cox1.  Section 1.3 details how 
SCO1 and SCO2 function to mature the CuA site of COX II. 
 
1.2.2.3 Biogenesis of sub-assembly intermediates during COX assembly 
COX assembly involves the formation of three distinct assembly intermediates (S1-S3) 
prior to maturation of the holoenzyme (Figure 1.6) (Fontanesi et al., 2008; Shoubridge, 2001; 
Soto et al., 2012).  In mammals, COX I is inserted and matured within the IMM to form S1.  
Two nuclear-encoded subunits, COX IV and COX Va, then associated with mature COX I to 
form S2.  A significant number of subunits, including mature COX II, are then added to the 
assembling holoenzyme to form S3.  The subsequent incorporation of COX VIa and COX VIIa/b 
into the S3 intermediate yields the mature holoenzyme (Nijtmans et al., 1998; Shoubridge, 2001; 
Soto et al., 2012) 
 
1.3 SCO1 and SCO2 
SCO1 and SCO2 were first identified as high-copy suppressors in a genetic screen of a 
Cox17 null yeast strain (Glerum et al., 1996b).  Overexpression of either protein suppressed the 
respiratory deficiency observed in the Cox17 null stain; however, subsequent deletion of each 
SCO gene demonstrated that only Sco1 was required for growth on a non-fermentable carbon 
source.  Overexpression of Sco2 was unable to rescue the glycerol growth defect of a Sco1 null 
strain, but was able to functionally complement a restricted subset of functionally compromised 
Sco1 point mutants (Glerum et al., 1996b).  Although this led to the suggestion that Sco1 and 
Sco2 fulfill partially overlapping functions, a defined role for Sco2 in COX assembly has yet to 
be established (Khalimonchuk and Rodel, 2005).  In contrast, both SCO genes are essential in 
humans (Valnot et al., 2000b, Papadopoulou et al., 1999), and each gene product is known to 
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fulfill independent but cooperative functions in the metallation of the CuA site of COX II (Horng 
et al., 2005; Leary et al., 2004; Leary et al., 2009; Leary, 2010).   
 
1.3.1 SCO1 and SCO2 functions during Cox assembly 
 Human SCO1 and SCO2 are both essential, and mutations in either gene lead to severe, 
early onset forms of fatal, tissue-specific disease.  To date, three unique mutations have been 
identified in SCO1 patients.  The first SCO1 patient died from liver failure and carried a P174L  
. 
Figure 1.6: Schematic of the step-wise addition of COX subunits to the assembling holoenzyme 
in humans.  Three intermediates (S1 – S3) are produced prior to the formation of the fully 
assembled holoenzyme (S4).  Progression through the various steps of assembly requires the 
synthesis, delivery and insertion of prosthetic groups, and the ordered incorporation of structural 
subunits, all of which are shown on the right hand side.  All aspects of assembly are facilitated 
by a large number of nuclear-encoded, accessory proteins termed COX assembly factors, which 
are shown on the left hand side (Redrawn from Shoubridge, 2001). 
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missense mutation on one allele, and a nonsense mutation on the second allele (Valnot et al., 
2000b).  Patients from the second SCO1 pedigree were homozygous for a G132S substitution 
and died from cardiac failure (Stiburek et al., 2009).  The patient from the third SCO1 pedigree 
was a compound heterozygote who harboured a M294V missense mutation on one allele and a 
nonsense mutation on the second allele, and who presented with a fatal encephalopathy (Leary et 
al., 2013a).  Mutations in SCO2 are far more common, and thus far more than 30 pedigrees have 
been identified.  The overwhelming majority of these pedigrees express at least one allele 
containing an E140K missense mutation (Jaksch et al., 2001; Mobley et al., 2009).  Although 
there is some clinical heterogeneity that is observed across SCO2 pedigrees, all patients 
eventually succumb from heart failure (Leary et al., 2006).  Why mutations in two closely related 
paralogues that function in the same biochemical pathway produce different, tissue-specific 
diseases remains an enduring mystery.   
 Human SCO1 and SCO2 are anchored to the IMM by a single-pass transmembrane 
domain, and gel filtration data argue that both proteins are homodimers in vivo (Leary et al., 
2004).  The C-terminus of each protein protrudes into the IMS, and has a highly conserved 
thioredoxin fold that contains a copper-binding site.  Cu(I) is coordinated by the two cysteines of 
a CxxxC motif and highly conserved histidine, while the coordination of Cu(II) requires another, 
as of yet unidentified ligand (Banci et al., 2006; Banci et al., 2007a).  Copper binding is essential 
to SCO protein function, and both proteins bind Cu(I) or Cu(II) in vitro (Leary et al., 2004).  
Replacing any of the copper-coordinating amino acids with alanines abrogates SCO1 and SCO2 
function, which provides further evidence that copper-binding is required for their activity 
(Horng et al., 2005).  Consistent with these observations, the isolated COX deficiency in SCO1 
and SCO2 patient cells can be rescued when exogenous copper is added to the culture media 
(Jaksch et al., 2001; Leary et al., 2004; Salviati et al., 2002).   
However, the exact relationship between copper-binding and SCO protein function in the 
context of COX assembly remains unknown, because it is unclear whether one or both SCO 
proteins transfer copper to COX II during the maturation of its binuclear CuA site.  How the 
proposed redox function of SCO1 (Williams et al., 2004) and the demonstrated thiol-disulphide 
oxidoreductase activity of SCO2 (Leary et al., 2009) affect COX assembly, if at all, remains 
equally unclear.  Further studies are therefore required to better understand the specific roles of 
each SCO protein during COX assembly. 
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1.2.3 SCO1 and SCO2 roles in copper homeostasis 
 Affected SCO patient tissues and fibroblasts are both COX and copper deficient, 
suggesting that SCO1 and SCO2 are bifunctional proteins that fulfill additional roles in the 
regulation of cellular copper homeostasis (Leary et al., 2007).  It was subsequently demonstrated 
that the cellular copper deficiency phenotype in SCO patient fibroblasts is caused by an elevated 
rate of copper efflux from the cell (Leary et al., 2007), and that this phenotype can be rescued to 
varying degrees by overexpressing SCO2.  Consistent with these observations, redox regulation 
of the CxxxC motif of SCO1 was recently shown to be critical to the generation of a SCO1-
dependent mitochondrial signal that regulates the rate of ATP7A-mediated copper efflux from 
the cell (Leary et al., 2013b).  Transduction of this signal is critically dependent on COX19, 
which partitions between the IMS and the cytosol in a copper-dependent manner that is perturbed 
in SCO patient cells.  These data collectively suggest a model whereby the redox regulation of 
the CxxxC motif of SCO1 generates a mitochondrial signal that is then transduced to ATP7A by 
COX19.  However, it is clear that other, as yet unidentified proteins are critical to sensing the 
functional status of SCO1 within the IMS, and transducing a SCO1-dependent redox signal to 
extra-mitochondrial compartments.   
In spite of the profound copper deficiency at the cellular level, mitochondrial copper 
pools are unaltered in SCO patient fibroblasts, suggesting that mechanisms exist to preferentially 
preserve the organellar metal ion pool (Dodani et al., 2011).  Almost nothing, however, is known 
about how copper is trafficked to, within and from mitochondria.  In fact, the first mitochondrial 
protein involved in organellar copper handling was only identified this year (Vest et al., 2013).  
Although strong genetic and biochemical evidence was presented that clearly implicate yeast 
Pic2 in copper transport across the IMM, several genetic and pharmacological stressors had to be 
applied to observe a copper deficient phenotype in a yeast Pic2 null mutant.  This suggests that 
the mitochondrion contains novel copper trafficking pathways that can functionally complement 
for the loss of Pic2 function.  The identification of these pathways, particularly in the context of 
copper mobilization from the matrix to the IMS for metallation of the CuA and CuB sites of COX 
during holoenzyme assembly, would be invaluable to our understanding of mitochondrial copper 
handling. 
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1.4 Rationale, hypothesis and objectives 
 SCO1 and SCO2 are IMM proteins that must be able to bind copper to function both as 
COX assembly factors and in a mitochondrial pathway that regulates cellular copper 
homeostasis.  Our understanding of how SCO1 and SCO2 fulfill their various functions is 
currently limited, because very few of their interacting partners have been identified.  I therefore 
hypothesize that by identifying interacting partners of SCO1 and/or SCO2, and characterizing 
the functional significance of these physical interaction, I will further our understanding of the 
mechanisms by which SCO proteins mature the CuA site of COX II and regulate cellular copper 
homeostasis.  The objectives of my M.Sc. thesis research then were to; 
1. Co-immunoprecipitate SCO1 and SCO2, and identify their interacting partners by mass 
spectrometry.  
2. Validate the observed interactions for a subset of the identified proteins by reciprocal 
co-immunoprecipitation, and use an RNAi approach to investigate the significance of 
these interactions to SCO protein function. 
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2 MATERIALS AND METHODS 
2.1 Reagents 
 Names of reagents and suppliers are listed in Table 2.1.   Addresses for each supplier are 
subsequently listed in Table 2.2. 
Table 2.1 List of reagents and suppliers 
General Reagents Supplier 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) 
BioShop 
Acetyl Coenzyme A Roche 
Acrylamide BioShop 
Agarose beads Sigma-Aldrich 
Ammonium persulfate (APS) BioShop 
Bathocuproine disulfonic acid (BCS) Sigma-Aldrich 
Bis-acrylamide BioShop 
Bis-tris Bioshop 
Blotto non-fat dry milk Bio-Rad 
Bovine serum albumin (BSA) BioShop 
Bradford protein assay reagent Bio-Rad 
Coomassie Brilliant BlueR-250  Bio-Rad 
Cupric chloride Sigma-Aldrich 
Digitonin, high purity CalbioChem 
Ethylenediaminetetraacetic acid (EDTA) Bioshop 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Bioshop 
2x Laemmli sample loading buffer Bio-Rad 
Monoclonal anti-HA-agarose beads Sigma-Aldrich 
n-Dodecyl-β -D-Maltoside (DDM) Bioshop 
Oxaloacetic acid Sigma-Aldrich 
Phosphate buffered saline (PBS) Bioshop 
Complete protease inhibitor cocktail Roche 
Sodium dodecyl sulfate (SDS) BioShop 
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SYBR-Green Invitrogen 
Taurodeoxycholic acid (t-DOC) Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Triethanolamine Sigma-Aldrich 
Triton X-100 Bioshop 
Tween-20 Bioshop 
Restriction and modifying enzymes Supplier 
BamHI Thermo Scientific 
NotI Thermo Scientific 
Phusion High-Fidelity DNA polymerase New England Biolabs 
T4 DNA Ligase New England Biolabs 
Cell Culture Reagents Supplier 
Antibiotic-antimyotic Invitrogen 
Dulbecco’s modified Eagle’s media (DMEM) Invitrogen 
Fetal bovine serum  Invitrogen 
Hygromycin B Calbiochem 
1,5-dimethyl-1,5-diazaundecamethylene 
polymethobromide, hexadimethrine bromide 
(Polybrene) 
Sigma-Aldrich 
Puromycin Sigma-Aldrich 
Trypsin-EDTA Invitrogren 
Bacteria Culture Reagents Supplier 
Ampicillin Bioshop 
Bacto-tryptone Bioshop 
Bacto-yeast Becton Dickinson 
Kanamycin Bioshop 
Chemical crosslinkers  
1,5-Difluoro-2,4-dinitrobenzene (DFDNB),  Thermo Scientific 
Dimethyl pimelimidate (DMP) Thermo Scientific 
Disuccinimidyl glutarate (DSG) Thermo Scientific 
Disuccinimidyl suberate  (DSS) Thermo Scientific 
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Disuccinimidyl tartarate (DST) Thermo Scientific 
Commercial kits Supplier 
AminoLink  Thermo Scientific 
Antarctic phosphatase New England Biolabs 
E.Z.N.A.  Plasmid Mini Kit Omega Bio-Tek 
Gel Extraction Kit Qiagen 
Glutathione-Sepharose beads GE  Life Sciences 
jetPRIME
TM 
DNA Transfection Reagent Polyplus Battery 
OneStep RT-PCR kit Qiagen 
Table 2.2 Names and addresses of suppliers 
Becton Dickinson Mississauga, Ontario, Canada  
Bioshop Burlington, Ontario, Canada 
Bio-Rad Mississauga, Ontario, Canada 
BectonDickinson Mississauga, Ontario, Canada 
Calbiochem-Millipore Billerica, MA, USA 
GE Life Sciences Baie d’Urfe, Quebec, Canada 
Invitrogen Burlington, Ontario, Canada 
New England Biolabs Whitby, Ontario, Canada 
Omega Bio-Tek Norcross, GA, USA 
Pall Missausaga, Ontario, Canada 
Polyplus Battery Berkeley, CA, USA 
ProteinTech Chicago, IL, USA 
Qiagen Toronto, Ontario, Canada  
Roche Mississauga, Ontario, Canada 
Santa Cruz Biotechnology Dallas, TX, USA 
Sigma-Aldrich Oakville, Ontario, Canada 
Thermo Scientific Waltham, MA, USA 
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2.2 Mammalian cells culture 
Primary skin fibroblasts were isolated from control subjects and from patients with 
mutations in SCO1 (SCO1-1, T146X/P174L (Valnot et al., 2000b); SCO1-2, V93X/M294V 
(Leary et al., 2013a) or SCO2 (SCO2-9, R90X/E140K (Leary et al., 2013)).  Primary fibroblast 
cultures were then immortalized by transduction with the E7 gene of the human papillomavirus 
and the catalytic subunit of human telomerase (Lochmuller et al., 1999).  Fibroblasts, Phoenix 
amphotropic packaging cells and HEK293 cells were grown in Dulbecco’s modified Eagle’s 
media (DMEM) supplemented with 10% fetal bovine serum and 1X antibiotic-antimyotic (Life 
technologies) at 37°C in an atmosphere of 5% CO2.  Immortalized fibroblasts and HEK293 cells 
were transduced using the Phoenix amphotropic packaging cell line (kind gift of Dr. G.  Nolan, 
Stanford University) and stable cell lines were selected by supplementing the culture media with 
100 mUnits/mL of hygromycin B (Calbiochem) or 2 µg/mL of puromycin (Sigma) (Leary et al, 
2007). 
2.3 Plasmids, bacterial strains and growth media 
For co-immunoprecipitations, retroviral expression vectors containing full-length, 
untagged or epitope-tagged cDNA variants of SCO1 and SCO2 were generated prior to my 
arrival in the lab.  SLC25A1 or SLC25A11 cDNAs were amplified by reverse-transcriptase PCR 
(RT-PCR) of RNA isolated from control fibroblasts, and subsequently cloned by homologous 
recombination into the retroviral overexpression vector pBABE using Gateway® cloning.   
Plasmids were amplified by transforming chemically competent DH5α or XL1-Blue E. coli 
strains.   
Glutathione-S-transferase (GST), GST-SCO1, and GST-SCO2 were expressed from 
pGEX-6P3 (a kind gift of Dr. Trevor Moraes, University of Toronto; GE Life sciences).  Plasmid 
DNA was then transformed into the chemically competent BL21 Rosetta E. coli strain (kind gift 
of Dr. Stan Moore, University of Saskatchewan), which contains a chromosomal copy of the T7 
RNA polymerase under control of the lac promoter.  Bacteria were therefore grown in media 
containing isopropyl β-D-1-thiogalactopyranoside (IPTG) to induce the expression of GST alone 
or GST-fusion proteins.   
All bacterial cultures were grown at 37°C in 2YT media (1.6% Bacto-tryptone, 1% 
Bacto-yeast, 85 mM NaCl, pH 7.4)  or 2YT agar plates (0.6% agar) containing 100 μg/mL 
ampicillin or 50 μg/mL of kanamycin. 
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2.4 DNA methods 
2.4.1 Subcloning 
2.4.1.1 Traditional cloning 
Crude polyclonal serum had been previously generated against short SCO1 
(CASIATHMRPYRKKS) and SCO2 (GRSRSAEQISDSVRRHMAAFRSVLS) peptide 
sequences (Jaksch et al., 2001; Leary et al., 2004).  Full-length SCO1 and SCO2 cDNAs were 
used to amplify these antigenic sequences by PCR.  The forward SCO primers contained a 
BamHI restriction site and a two glycine linker 5’ of the first codon, while the reverse SCO 
primers had a NotI restriction site 3’ of the terminal codon (Table 2.1).  PCR amplification of 
each SCO fragment was carried out in a 20 µL volume containing 1X Phusion HF buffer, 200 
µM dNTPs, 0.4 units of Phusion polymerase, 0.5 µM of each primer, and 10 ng of template 
plasmid.  Cycling conditions consisted of an initial denaturation for 3 minutes at 98°C, followed 
by 30 cycles of 10s denaturation at 98°C, annealing of 30s at 52°C and extension of 15s for 
72°C.  A final extension of 3 minutes at 72°C was used after the completion of all the cycles.  
Successful amplification was confirmed by running 10% of the reaction on a 2.5% agarose gel 
containing nucleic acid stain (1X SYBR-Green).  The remainder of the PCR reaction was 
precipitated by adding 0.3 M sodium acetate, 0.1 M magnesium chloride and 70% ethanol.  
Samples were incubated at -20°C for 45 minutes and then pelleted at 14,000 x g for 15 minutes at 
4°C.  The pellet was resuspended with 70% ethanol and left at -20°C for 45 minutes again.  
Following a second spin at 14,000 x g for 15 minutes at 4°C, the supernatant was removed and 
the pellet was allowed to dry at room temperature for 10 minutes.  The pellet was then 
resuspended in triple distilled water and the entire sample was used for subsequent digestions.   
Both the parental pGEX-6P3 plasmid (2 µg) and SCO amplicons were digested for 60 
minutes at 37°C in a 10 µL volume containing 1X Fermentas fast digest buffer, 5 Units of 
BamHI and 5 Units of NotI.  Restriction enzymes were then heat inactivated by incubating 
samples at 65°C for 5 minutes.  Following the addition of 1X Antarctic phosphate buffer and 2 
Units of Antarctic phosphatase (New England Biolabs), the linearized pGEX-6P3 plasmid was 
incubated for 20 minutes at 37°C and then heat inactivated at 65°C for 5 minutes.  Ligations 
were subsequently performed in 20 µL volumes that contained 1X T4 DNA Ligase buffer, 1 µL 
T4 DNA Ligase, 1 µL of linearized, desphosphorylated pGEX-6P3 plasmid and 2.5 µL of the 
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digested SCO amplicon.  Ligation reactions were left overnight at room temperature.  The 
following day, 5 µL of the ligated reaction was transformed into XL-1 Blue E. coli cells.   
 
2.4.1.2 Gateway® cloning 
Full-length SLC25A1 and SCL25A11 cDNAs were amplified and cloned by homologous 
recombination into the Gateway adapted mammalian retroviral overexpression vector pBABE-
puro (Figure 2.1).  Total RNA was isolated from control fibroblasts using an RNA purification 
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Table 2.3: List of primers 
Primer name Primer sequence 
3’ NotI pGEX-SCO2 CGTGCGGCCGCCTAGTGATCCAGCAGGTGGAGTC 
            NotI 
3’ NotI pGEX-SCO1 CGTGCGGCCGCCTAGCTCTTTTTTCTGTATGGC 
            NotI 
5’ BamH1 pGEX-
SCO2 
GCAGGATCCGGAGGTGGCGGAGGTGGTCGAACAGAAGCCCTG 
           BamHI 
5’ BamHI pGEX-
SCO1 
GCAGGATCCGGAGGTGGCGGAGGTGGTAGGAAGGGACAAATA 
           BamHI 
Gateway attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCT 
Gateway attB2 GGGGACCACTTTGTACAAGAAAGCTGGGT 
Gateway 
SLC25A11-F 
AAAAAGCAGGCTTCACCATGGCGGCGACGGCGAGT 
Gateway 
SLC25A11-R 
AGAAGCTGGGTGTTATCAGCCACTGAGGAAGAGAC 
Gateway SLC25A1-
F 
AAAAAAGCAGGCTTCACCATGCCCGCGCCCCGCGCC 
Gateway SLC25A1-
R 
AGAAAGCTGGGTGTTATTCGTCCGTCTTCCACACTTTGTT 
 
 
kit (Norgen), and then used as a template in a OneStep RT-PCR reaction (Qiagen) with primers 
designed to amplify each full-length cDNA such that it contained a partial attB1 and attB2 site at 
its 5’ and 3’ end, respectively (Table 2.1).  PCR amplicons were separated on a 1.5% agarose 
gel, excised and extracted using a Gel Extraction Kit (Qiagen).  Purified amplicons were then 
used in a subsequent PCR reaction with universal attB1 and attB2 primers to generate complete 
attB homology arms, and the amplicons were then cloned into the Gateway® entry level donor 
vector, pDONR, according to manufacturer’s instruction.  After confirming the authenticity of 
each construct in pDONR, each SCO cDNA was transferred by a second homologous 
recombination reaction to the destination vector, pBABE-puro. 
To ensure the fidelity of all constructs; plasmids were submitted to the NRC Plant 
Biotechnology Institute (Saskatoon, SK) for Sanger sequencing. 
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2.4.2 Bacterial transformation 
XL-1 Blue or DH5α E. coli strains were used for plasmid amplification, and Rosetta BL-
21 E. coli were used for expression for GST and GST fusion proteins.  Chemically competent 
bacteria were thawed on ice for 10 minutes, and less than 5 µL of plasmid DNA (10 ng) was 
subsequently added to 30 – 50 µL.  Bacteria were then incubated on ice for 30 minutes, heat 
shocked  at  42°C  for  45  seconds  and  cooled  on ice for 2 minutes.  Bacteria were diluted with 
500 µL of pre-warmed SOC media (2% Bacto-tryptone, 0.5% Bacto-yeast, 10 mM MgCl2, 2.5 
mM KCl, 8.5 mM NaCl, and 20 mM glucose) and allowed to recover for 1 hour at 37°C while 
shaking (225 rpm) prior to plating on 2YT media containing either ampicillin (100 µg/mL) or 
kanamycin (50 µg/mL).  Plasmids were isolated and digested using the appropriate restriction 
enzymes prior to sequencing to ensure their integrity.   
 
2.4.3 Plasmid isolation and DNA quantification 
Plasmid DNA was isolated from chemically competent E. coli strains using the E.Z.N.A 
plasmid mini-prep kit according to the manufacturer’s instructions.  Isolated DNA was diluted 
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Figure 2.1: Description of Gateway® cloning 
 
1:20 with triple-distilled water, and quantified by measuring the absorbance at 260 nm using a 
SpectraMAX 190 microplate spectrophotometer (Molecular Devices).   
 
2.5 Retroviral transduction 
Human fibroblasts or HEK293 cells were retrovirally transduced with vectors containing 
cDNAs that allowed for the overexpression of epitope tagged SCO1 or SCO2 variants or the 
metabolite transporters SLC25A1 or SLC25A11.  Retrovirus was packaged using the Phoenix 
Amphotropic helper-free production system and then used to transduce cell lines as follows; 
 Day 1; Transfection of Phoenix cells.  Phoenix cells were grown to 60-80% confluence 
and given fresh pre-heated media the day of transfection.  JetPRIME™ Transfection Reagent 
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was used to transfect plasmid DNA according to manufacturer’s instructions.  Solution was 
added drop wise to the plate and then the Phoenix cells were placed in the incubator for 24 hours.   
 Day 2; Detoxification of Phoenix cells.  Twenty-four hours post-transfection, media was 
replaced with fresh media to obtain a higher viral titer.   
 Day 3; Transduction of human fibroblasts or HEK293 cells.  The retroviral-containing 
media was harvested 48 hours after transfection with plasmid DNA and filtered through a 0.45 
µm filter.  Polybrene, a cationic polymer that promotes viral infection, was added (5 µg/mL), and 
sufficient retroviral filtrate was subsequently added to cover the human fibroblasts or HEK293 
cells (confluence between 40% and 60%).  Cells were placed in the incubator for 2 hours and 
followed by the addition of fresh media containing polybrene. 
 Day 4 and 5; Selection for stable overexpressing cell lines.  Twenty-four hours post-
transduction the media was replaced with fresh media.  Forty-eight hours post-transduction the 
selective agent, either 100 mUnits/mL hygromycin B or 2 ng/mL puromycin, was added.  Cells 
were maintained in media supplemented with the appropriate selection agent.   
 
2.6 Protein isolation 
2.6.1 Protein concentration 
The Bradford assay was used to quantify the protein concentration of all samples 
(Bradford, 1976).  A standard curve was established using BSA (1 µg – 8 µg or 0.25 µg – 8 µg) 
in a 96-well plate.  Samples (1 – 2 µL) were added to wells, and both the standards and samples 
were diluted with 250 µL of Bradford protein assay (Biorad).  Absorbance was measured at 595 
nm, and the protein concentration of samples was calculated using the BSA standard curve. 
 
2.6.2 Whole cell extracts 
Cells were harvested by trypsinization or manual scraping, and pelleted at 10,000 x g for 
1 minute at 4°C.  The resultant pellets were resuspended in ice-cold PBS, and centrifuged once 
again at 10,000 x g for 1 min at 4°C.  Following protein quantitation, cells were resuspended at 4 
mg/mL in PBS containing 1.5% n-Dodecyl-beta-D-Maltoside (DDM; BioShop) and a 1X 
protease inhibitor cocktail (PIC; Roche), and then lysed at 4
o
C for 40 min.  Lysates were 
clarified by centrifugation at 10,000 x g for 10 min at 4°C, and supernatants were removed and 
used for subsequent analyses. 
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2.6.3 Isolation of digitonized mitoplasts 
An enriched mitoplast fraction was isolated from fibroblasts that had been transfected 
with control small-interfering RNA (siRNA) or COX20 siRNA, as previously described 
(Klement et al., 1995).  Briefly, cells were washed with PBS, trypsinized and then neutralized.  
Cell pellets were washed with ice-cold PBS containing 1X PIC, and pelleted at 10,000 x g for 1 
minute at 4°C.  Following protein quantitation, cells were resuspended at 5 mg/mL in ice-cold 
PBS.  An equal volume of 4 mg/mL of digitonin (Calbiochem) resuspended in PBS was then 
added, and samples were incubated on ice for 10 minutes.  Mitoplasts were isolated at 10,000 x g 
for 10 minutes and lysed for 30 minutes on ice in PBS containing 1.5% DDM and 1X PIC.  
Samples were vortexed every 5 minutes, and the clarified supernatants were removed after 
samples had been centrifuged at 16,000 x g for 10 minutes at 4°C and used for subsequent 
immunoblot analysis.   
 
2.7 Co-immunoprecipitations 
2.7.1 Purification of SCO1 antibodies from polyclonal serum 
SCO1 or SCO2 antibodies were affinity purified by sequential incubation of crude 
polyclonal serum with a GST column and the appropriate GST-SCO fusion column.  BL-21 
Rosetta E. coli cultures were transformed with pGEX-6P3 plasmids coding for GST alone, GST-
SCO1 or GST-SCO2 fusion proteins containing the peptide sequence to which the relevant SCO 
antibody was raised against.  Bacteria were grown overnight in 20 mL of 2-YT media containing 
100 µg/mL ampicillin, diluted in 1 L of 2-YT media the next morning and grown until the A600 
was 0.4.  IPTG (0.5 mM) was then added to the shaking culture, and protein expression was 
induced for 4 hours at 25°C.  Bacteria were subsequently pelleted at 4000 x g for 5 minutes at 
4°C, and washed once with ice cold PBS.  Cultures were pelleted again and lysed in a buffer 
composed of 50 mM Tris (pH 7.0), 150 mM sodium chloride, 1X PIC, 1 mM 
ethylenediaminetetraacetic acid (EDTA) and 1 mg/mL lysozyme for 45 minutes, follow by 
sonication on ice three times for 5 second intervals using a Sonifer cell disruptor (Heat systems-
ultrasonics) at power level 7.  Lysate was incubated with Glutathione-Sepharose beads (GE Life 
Sciences) and then washed three times with PBS, according to manufacturer’s instructions.  GST 
protein was subsequently eluted from the beads using 10 mM reduced glutathione in 50 mM Bis-
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Tris at pH 8.0, and purity was verified by staining an sodium dodecyl sulfate (SDS)-PAGE gel 
with Coomassie Brilliant Blue R-250 (Bio-Rad).  Purified GST and GST-fusion proteins were 
then covalently bound to aldehyde-activated agarose AminoLink columns, as per manufacturer’s 
instructions (Thermo Scientific). 
Crude polyclonal SCO1 or SCO2 serum was pre-cleared by incubating it with GST 
coupled AminoLink columns.  The flow through was then incubated with AminoLink columns to 
which the relevant GST-SCO fusion proteins had been coupled, and washed with two column 
volumes of PBS.  Purified antibody was subsequently eluted with 5% acetic acid, which was 
immediately neutralized with 2 M Tris.  Eluted antibody was concentrated and buffer exchanged 
in PBS using a 30 kDa centrifugal device (Pall), diluted with an equal volume of glycerol and 
stored at -20°C.   
 
2.7.2 Mitochondrial isolation by differential centrifugation 
Mitochondria used in co-immunoprecipitations were isolated by differential 
centrifugation.  Confluent plates of either HEK293 cells or fibroblasts were washed once with 
PBS, and manually scraped.  Cells were pelleted at 200 x g for 5min, and resuspended in STE 
buffer (10 mM Tris [pH 7.5], 0.25 M sucrose and 1 mM EDTA).  Cells were subsequently 
homogenized on ice with ten strokes in a zero clearance Potter elvehjem homogenizer.  
Homogenate was centrifuged at 600 x g for 10 min at 4°C.  The resultant supernatant was 
removed and spun down again at 600 x g for 10 min at 4°C.  The second supernatant was then 
centrifuged at 8000 x g for 10 min at 4°C.  The pellet was resuspended in STE buffer 
supplemented with 1X PIC.  Homogenate was centrifuged again at 8000 x g for 10 min at 4°C 
and washed once with HIM buffer (220 mM mannitol, 70 mM sucrose, and 1 mM ethylene 
glycol tetraacetic acid (EGTA) in 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) at pH 7.5).  Pellet was resuspended in 1 mL of HIM buffer and the total protein content 
was quantified by Bradford assay.  Mitochondrial isolate was pelleted a final time and aliquots 
were stored at -80°C.   
  
2.7.3 Incubation with chemical crosslinker 
Homobifunctional crosslinkers reactive towards primary amines were used to stabilize 
protein-protein interactions, based on previously established protocols (Sasarman et al., 2010).  
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Frozen aliquots of isolated mitochondria were diluted to 0.33 mg/mL in HIM buffer containing 
300 µM chemical crosslinker.  Three different crosslinkers with increasing spacer arm lengths 
were used; 1,5-Difluoro-2,4-dinitrobenzene (DFDNB), disuccinimidyl glutarate (DSG) and 
disuccinimidyl suberate  (DSS).  Incubation with a given crosslinker was done for 60 minutes on 
ice, with reactions being quenched by adding 80 mM glycine (pH 8.0) for 10 minutes.  
Crosslinked mitochondria were subsequently pelleted at 10,000 x g for 10 minutes at 4°C, and 
lysed at 3.5 mg/mL in 50 mM HEPES (pH 7.6), 150 mM NaCl, 1% taurodeoxycholic acid (t-
DOC) and 1X PIC.  After 40 minutes on ice, lysates were clarified by centrifugation at 16,600 x 
g for 40 minutes at 4°C. 
 
2.7.4 Preparation of magnetic beads 
Antibodies were crosslinked to protein A or protein G DynaBeads (Invitrogen) using a 
combination of the manufacturer’s instructions and a previously established protocol (Sasarman 
et al., 2010).  Briefly, dynabeads were washed three times with 0.1 M Na-phosphate (pH 8.0).  
An antibody solution containing 0.1 M Na-phosphate was then mixed with the Dynabeads at a 1 
µL of bead solution:1 µg of antibody ratio, and rotated overnight at 4°C.  The next day the 
antibody solution was removed, washed once with NaP-W1 (0.1 M Na-phosphate [pH 8.0], 
0.08% Tween-20) and twice with TEA-W (0.2 M triethanolamine [pH 8.0], 0.08% Tween-20).  
Antibodies were then chemically coupled to protein A or protein G Dynabeads by incubating for 
30 minutes in TEA-W containing 5.4 mg/mL dimethyl pimelimidate (DMP), a reversible 
homobifunctional crosslinker reactive towards amines.  The crosslinking solution was removed 
and crosslinking was quenched by incubating the beads for 15 minutes in a buffer containing 50 
mM Tris (pH 7.5) and 0.08% Tween-20.  Beads were then washed three times with NaP-W1 and 
excess, unbound antibody was eluted with two consecutive 10 minute incubations in 0.1 M 
glycine (pH 2.5) containing 0.08% Tween-20.  Beads were washed three more times with NaP-
W1 prior to incubating antibody-crosslinked Dynabeads with mitochondrial extracts.  All the 
wash and incubation volumes were 10 fold the bead volume, except for the 3 NaP-W1 washes 
prior to antibody incubation, and the first NaP-W1 wash prior to DMP crosslinking which were 5 
fold the bead volume.  Elution volumes were equivalent to the bead volume.  In co-
immunoprecipitation experiments where beads-alone controls were used, DynaBeads were taken 
through this protocol without any antibody. 
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2.7.5 Co-immunoprecipitations with or without chemical crosslinkers 
Lysed mitochondrial extracts that had been chemically crosslinked were incubated with 
SCO1 or FLAG coupled DynaBeads, or Dynabeads alone.  For SCO2-HA co-
immunoprecipitations, commercially available agarose beads coated with HA antibodies (Sigma-
Aldrich) were used along with agarose beads alone.  Samples were incubated with beads 
overnight at 4°C with rotational mixing.  The next morning, beads were washed five times with 
NaP-W2 (0.1 M Na-phosphate [pH 8.0], 0.08% Tween-20 and 0.05% t-DOC), and the beads 
were incubated for 10 minutes in 5% acetic acid to elute bound protein.  Eluate was immediately 
neutralized with 2 M unbuffered Tris.  Beads were then washed one time with 0.1 M Na-
phosphate (pH 8.0) and boiled in 1 X Laemmli sample loading buffer (Bio-Rad) with 100 mM 
dithiothreitol (DTT).   
Co-immunoprecipitations were also performed in the absence of chemical crosslinkers.  
In these experiments, isolated mitochondria were resuspended at 1.5 mg/mL in a buffer 
containing 20 mM Tris (pH 7.5), 50 mM potassium chloride, 0.4% DDM and 1X PIC, and lysed 
for 5 minutes on ice.  Extracts were centrifuged at 16,000 x g for 30 minutes at 4°C, and the 
supernatant was incubated overnight at 4°C with rotational mixing with DynaBeads alone or 
antibody coupled Dynabeads.  The next morning, beads were washed three times with a buffer 
composed of 20mM Tris (pH 7.5) and 50 mM KCl, and the bound protein was eluted by boiling 
in sample loading buffer supplemented with 100 mM DTT.   
 
2.7.6 Mass spectrometric analysis 
For co-immunoprecipitations involving chemical crosslinkers, 20% of the eluate was 
reserved for Western blot analysis.  The remainder of the eluate was precipitated by adding 15% 
trichloroacetic acid (vol/vol).  Samples were vortexed and incubated on ice for 30 minutes prior 
to being stored overnight at -80°C.  The next morning, samples were thawed on ice and pelleted 
at 20,000 x g for 30 minutes at 4°C.  Pellets were washed twice with ice cold acetone, and 
recentrifuged at 20,000 x g for 15 minutes at 4°C in between each wash.  Pellets were 
subsequently allowed to dry for 10 minutes at room temperature.  Dried pellets were then sent to 
the Institut de Recherches Cliniques de Montréal, where they were resuspended, trypsinized and 
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analyzed by LC-MS using an OrbiTrap mass spectrometer.  Peptide fragments were assigned to 
proteins computationally using Scaffold software and the human UniProt protein database.   
 
2.8 Small interfering RNA transfections 
Stealth RNAi™ siRNA was designed to target either SLC25A1, or SLC25A11, while constructs 
against COX20 were kind gifts from Dr. Antonio Barrientos, University of Miami (Invitrogen).  
BLOCK-iT™ Alexa Fluor Red scrambled siRNA is not homologous to any known gene and was 
used monitor transfection efficiency (Invitrogen) (Table 2.4).  Control and patient fibroblasts 
were transfected with 12.5 nM siRNA using Lipofectamine RNAiMAX on days 0, 3 and 6 when 
cells were 40-50% confluent.  Cells when then harvested either on day 8 for SLC25A1 and 
SLC25A11, or day 9 for COX20 knockdowns.   
 
2.9 Protein visualization techniques 
2.9.1 SDS-Polyacrylamide gel electrophoresis (PAGE) 
Cellular extracts or fractions from co-immunoprecipitations were separated by SDS-PAGE prior 
to Western blotting or Coomassie blue staining.  Samples were mixed with an equal volume of 
2X Laemmli sample loading buffer containing 200 mM DTT.  Samples were boiled for 5 
minutes, or incubated for 10 minutes at 37°C prior to being loading onto SDS-PAGE gels.  Pre-
cast Criterion (Bio-Rad) or homemade 4-20% gels and manually poured 12% and 15% fixed 
percentage SDS-PAGE gels were used.  The gels were run for 30 minutes at 90 V to allow the 
Table 2.4: List of Stealth RNAi™ constructs 
Description Exon targeted Invitrogen Stealth Oligo ID # 
BLOCK-iT™ Alexa Fluor 
Red scrambled 
N/A  
SLC25A1-1 9 HSS185938 
SLC25A1-2 8,9 HSS109962 
SLC25A1-3 7,8 HSS109961 
SLC25A11-1 6,7 HSS112215 
SLC25A11-1 2,3 HSS112214 
SLC25A11-1 2,3 HSS112213 
COX20 siRNA1 1,2 HSS151056 
COX20 siRNA2 2 HSS151057 
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samples to enter the resolving phase, at which point the voltage was increased to 110V for 30 
minutes.  The voltage was then increased to 130V until the dye front reached the bottom of the 
gel, and electrophoresis was discontinued. 
 
2.9.2 Western blotting 
For immunoblotting experiments, 10-30 µg of protein was loaded per lane and separated 
by SDS-PAGE or BN-PAGE.  Proteins were transferred to nitrocellulose using semi-dry transfer 
(Transblot SD from Biorad).  Membranes were subsequently blocked overnight with rotational 
mixing at 4°C with either 5% BSA or 5% Blotto non-fat dry milk (Santa Cruz) dissolved in the 
appropriate TBST or PBST.  Membranes were then incubated overnight at 4°C with rotational 
mixing in primary antibody solution.  Unpurified polyclonal SCO1 (1:200) and SCO2 (1:200), 
Porin (1:1000) (Millipore), SD70 (1:10000), and COX II (1:1000) (Mitosciences) were diluted in 
5% BSA in 20 mM Tris, 135 mM NaCl and 0.1% Tween-20 (Jaksch et al., 2001; Leary et al., 
2004).  Affinity-purified SCO1 (1:1000) and COX20 (1:1000; kind gift of Dr. Antonio 
Barrientos, University of Miami) antibodies were diluted in 5% Blotto non-fat dry milk in TBST 
(25 mM Tris [pH 7.4], 135 mM NaCl, 2.5 mM KCl and 0.1% Tween-20).  SLC25A1 (1:1000) 
and SLC25A11 (1:1000) (ProteinTech) were diluted in 5% Blotto non-fat dry milk in PBS with 
0.05% Tween-20.  Following incubation in affinity purified primary antibody, membranes were 
washed six times for five minutes per wash.  Membranes incubated with crude antisera were 
washed six times for 30 minutes per wash.  Membranes were then incubated for 60 minutes at 
room temperature with rotational mixing in the appropriate horseradish peroxidase conjugated 
secondary antibody (1:5000, BioRad).  Washes were subsequently repeated, and the abundance 
of each protein was detected by regular (Cell Signaling) or enhanced (West-Femto, Thermo-
Scientific) chemiluminescence.   
 
2.9.3 Coomassie blue staining 
Coomassie Brilliant Blue R-250 was used to stain SDS-PAGE gels to visualize the 
complexity of the eluate in SCO1-FLAG co-immunoprecipitations or confirm successful 
purification of GST proteins.  Following electrophoresis, SDS-PAGE, gels were washed once 
and fixed for 30 minutes with destain solution (45% methanol and 10% acetic acid).  The gel was 
then stained for either 60 minutes or overnight in destain solution containing 0.3% Coomassie 
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Brilliant Blue.  Gels were washed with destain solution and rotational mixing until the majority 
of the background was removed, imaged and stored at 4
o
C in 10% acetic acid. 
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3 RESULTS 
3.1 Optimization of chemical crosslinking conditions 
Co-immunoprecipitations of SCO1 and SCO2 were conducted to identify their potential 
interacting partners.  Because metallochaperones typically associate with their partners through 
weak and highly transient interactions (Chen et al., 2013), the potential utility of chemical 
crosslinkers was first evaluated.  The goal of these initial experiments was to determine optimal 
conditions for crosslinker driven formation of higher-order adducts specific to SCO proteins.  
Isolated mitochondria were incubated with DFDNB, DSG or DSS, three amine reactive, 
homobifunctional crosslinkers that differ only in their spacer arm length.  The effect of adding 
copper, reductant or respiratory substrates to the buffer on the efficiency of crosslinking was also  
 
Figure 3.1: Immunoblot analysis of HEK293 mitochondria incubated in the absence or presence 
of crosslinker. (A) Structures of DSG and DSS, the two homobifunctional compounds used in 
crosslinking experiments. (B) Isolated mitochondria isolated were incubated in buffer with or 
without copper, and in the same buffer supplemented with DSG or DSS crosslinkers.  Proteins 
were extracted and separated on a 4-20% SDS-PAGE gel, and membranes were immunoblotted 
with unpurified SCO1 or SCO2 antibody.   
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considered.  DSG produced the largest increase in the abundance of higher-order, crosslinked 
SCO protein adducts, an effect that was independent of adding any of the aforementioned 
elements to the buffer (Figure 3.1 and data not shown).  However, Western blotting with our 
crude SCO1 or SCO2 antiserum showed that these reagents were not suitable for co-
immunoprecipitations, because there was a significant amount of non-specific background, even 
in the absence of crosslinking.   
 
3.2 Co-immunoprecipitation of epitope-tagged SCO1 and SCO2 
3.2.1 Characterization of epitope-tagged SCO1 and SCO2 
To improve the signal to noise of the experiment, several C-terminal, epitope-tagged 
variants of SCO1 (SCO1-FLAG, SCO1-Tev/6xHis) and SCO2 (SCO2-HA, SCO2-Tev/6xHis) 
that had been developed prior to my arrival in the lab were used.  Like the wild-type proteins, 
retroviral overexpression of all epitope-tagged SCO variants rescued the COX deficiency in the 
relevant SCO patient cells, and further reduced residual COX activity in the reciprocal SCO 
patient background (data not shown).  To compare the abundance of epitope-tagged SCO 
variants to that of endogenously expressed SCO proteins, HEK293 cells were transduced with 
retrovirus packaging each of the SCO cDNAs and whole cell extracts were analyzed by Western 
blotting.  The steady-state levels of each epitope-tagged SCO protein were significantly higher 
than those of either endogenous SCO1 or SCO2 (Figure 3.2).  Although forced overexpression 
systems may promote non-specific interactions between proteins, these epitope tags can be 
detected with high quality, commercially available monoclonal antibodies.  Therefore, epitope-
tagged SCO proteins represented attractive targets for the affinity purification of crosslinked 
SCO protein complexes. 
 
3.2.2 Stabilization of protein-protein interactions by chemical crosslinking  
To ensure that the signal to noise was indeed improved and that the epitope tag itself did 
not promote non-specific crosslinking, crosslinking experiments were repeated in mitochondria 
isolated from HEK293 cells overexpressing each of the epitope-tagged SCO proteins (Figure 
3.3).  As expected, the use of antibodies against the epitope tags markedly reduced background 
immunoreactivity.  Western blotting of uncrosslinked and crosslinked protein extracts confirmed 
the presence of an immunoreactive band of ~60 kDa, consistent with the previous observation 
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that SCO proteins exist as homodimers in vivo (Leary et al., 2004).  Because detection of the 
dimer requires the presence of an epitope tag, the immunoreactive dimers that were observed 
may consist solely of epitope-tagged SCO proteins or be comprised of an epitope-tagged SCO 
and a wild-type protein.  However, in addition to the monomeric and dimeric form of each SCO 
protein, a non-specific band was observed for both of the 6x His-tagged SCO proteins, in the 
presence or absence of crosslinking.  For this reason and because of their higher relative 
expression levels (Fig 3.3), HEK293 cells overexpressing SCO1-FLAG or SCO2-HA were used 
for subsequent co-immunoprecipitations. 
 
3.2.3 Co-immunoprecipitation of SCO1-FLAG or SCO2-HA 
To identify potential interacting partners of SCO1 and SCO2, SCO1-FLAG or SCO2-HA 
were co-immunoprecipitated from mitochondria isolated from HEK293 cells.  Crosslinked 
mitochondrial extracts were precleared and then incubated with either FLAG or HA antibodies 
conjugated to beads.  Beads were washed, and bound protein was eluted first by incubating in 
5% acetic acid and then by boiling in sample loading buffer.  Western blot analysis of each 
fraction  confirmed  the  successful  affinity  purification  and  elution  of  SCO1-FLAG  and  
 
 
Figure 3.2: Immunoblot analysis of epitope-tagged SCO1 and SCO2 overexpression in HEK293 
cells.  Whole cell extracts from HEK293 cells stably expressing each SCO variant were lysed 
and separated on a 12% SDS-PAGE gel.  Membranes were blotted with crude antiserum that 
specifically recognizes SCO1 or SCO2.  Baseline denotes untransduced HEK293 cells.   
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SCO2-HA from the beads (Figure 3.4).  For both the anti-FLAG and anti-HA 
immunoprecipitations, the yield of epitope-tagged SCO protein recovered in the eluate was 
substantially lower than that which would be predicted based on the observed immunodepletion 
of the input.  However, SCO1-FLAG and SCO2-HA were never detected in the wash fractions 
and were not recovered by further elution steps (data not shown).  Despite the inexplicable loss 
of some of the immune complex, the eluates contained both endogenous and epitope-tagged SCO 
proteins, and there was good concordance between the immunoreactivity observed by Western 
blotting and the major protein species detected by Coomassie staining of the E2 fraction.  
Crosslinked SCO1-FLAG and SCO2-HA eluates were therefore analyzed by mass spectrometry, 
to identify the protein constituents of the E1 fraction (Figure 3.4).   
 
3.2.4 Mass spectrometric analysis of the eluates 
Co-immunoprecipitations were repeated as described above, and extracts from DSG crosslinked 
mitochondria were incubated with an antibody:bead conjugate or beads alone, to control for 
 
 
Figure 3.3: Immunoblot analysis of uncrosslinked and crosslinked mitochondrial extracts derived 
from HEK293 cells.  Mitochondria were isolated from untransduced HEK293 cells or from 
transduced cells overexpressing SCO1-FLAG, SCO1-Tev/6xHis, SCO2-HA, or SCO2-
Tev/6xHis.  Mitochondria were incubated in the absence or presence of DSG, lysed, and protein 
extracts were subsequently separated on a 4-20% SDS-PAGE gel.  Membranes were then blotted 
with the appropriate primary antibody; for example, HEK293 cells expressing SCO1-FLAG 
were blotted with α-FLAG and untransduced cells were blotted using crude antibody specific for 
SCO1 or SCO2. 
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non-specific protein binding.  One tenth of the protein eluted by acetic acid was analyzed by 
Western blotting to confirm that each epitope-tagged SCO protein had been successfully 
immunoprecipitated, and the remainder of this eluate was analyzed by LC-MS to identify its 
protein constituents.  A total of 542 and 436 proteins were identified in the SCO2-HA and 
SCO1-FLAG eluates, respectively.  Although neither SCO protein was identified in the 
reciprocal co-immunoprecipitation, known COX assembly factors, including COX18 and 
COX20 (Hell et al., 2000; Tzagoloff and Dieckmann, 1990), and the COX II structural subunit 
of the COX holoenzyme (Capaldi, 1990) were detected in both pulldowns.  However, a large 
number of unrelated structural proteins, subunits of the other oxidative phosphorylation 
complexes and mitochondrial proteases were also identified.  The disproportionate number of 
quality control proteins present in the eluates of each co-immunoprecipitation suggested that the 
overexpression of epitope-tagged SCO proteins may be promoting non-specific interactions, or 
favouring interactions with proteases.  Therefore to determine whether the observed interactions 
reflected real biology or were an artefact of the overexpression system, co-immunoprecipitations 
of endogenous SCO proteins were attempted. 
 
3.3 Co-immunoprecipitations of endogenous SCO1 and SCO2 
3.3.1 Purification of SCO1 and SCO2 antibodies 
Crude polyclonal antisera raised against peptide sequences from SCO1 or SCO2 were 
affinity purified.  However, sequential purification of SCO1 and SCO2 antibodies on a GST 
column and the appropriate GST-SCO fusion protein column, only yielded a useful analytical 
reagent for SCO1 (Figure 3.5, data not shown).  Because of the inability to generate an affinity-
purified SCO2 antibody, the focus of the remainder of my M.Sc. project shifted towards 
identifying potential interacting partners of SCO1. 
 
3.3.2 Validation of affinity-purified SCO1 antibody for co-immunoprecipitation 
experiments 
The ability to co-immunoprecipitate endogenous SCO1 opened up the possibility of 
identifying interacting partners in control cells, and investigating whether these interactions were 
perturbed in patient cells that harbour alleles with pathogenic mutations in SCO1 or SCO2.  
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Fibroblasts from the SCO1-2 patient were included in these experiments, even though the steady-
state levels of the SCO1 M294V variant are less than 5% of those of the wild-type protein in 
control and SCO2 patient cells (Figure 3.6). 
To ensure that our affinity-purified SCO1 antibody is able to detect crosslinked SCO1 
protein adducts, isolated mitochondria from control and SCO1-2 patient fibroblasts were 
incubated in the presence or absence of DSG and analyzed by Western blotting.  A significant 
accumulation of higher order, crosslinked adducts was observed in control cells, but not in 
 
 
  
Figure 3.4: Immunoblot and Coomassie stain analyses of SCO1-FLAG (A) and SCO2-HA (B) 
co-immunoprecipitations.  Crosslinked mitochondrial extracts were precleared with beads devoid 
of antibody, and then incubated overnight with antibodies specific for the appropriate epitope.  
After five washes, beads were first eluted with acetic acid (E1), and residual protein was removed 
by boiling in sample loading buffer with reductant (E2).  Equal fractions (10%) of each sample 
were separated by SDS-PAGE and membranes were blotted with the indicated primary 
antibodies.  The remainder of the E2 fraction (90% of total) was loaded on a separate SDS-PAGE 
gel, and post-stained with Coomassie blue to visualize the total protein profile.  Bands 
corresponding to the light and heavy chains are labelled with an asterisk.   
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in SCO1-2 patient fibroblasts (Figure 3.7), arguing that the affinity-purified antibody is capable 
of specifically pulling down crosslinked adducts containing endogenously expressed SCO1.   
 
 
Figure 3.5: Comparative analysis of membranes blotted with either crude or affinity-purified 
SCO1 antiserum.  Whole cell extracts (WCE) from HEK293 cells and mitochondrial (Mt) 
extracts from HEK293 cells and fibroblasts (F) were separated by SDS-PAGE.  Membranes were 
subsequently blotted with crude or purified SCO1 antibodies. 
 
 
Figure 3.6: Immunoblot analysis of SCO1 abundance in fibroblasts and HEK293 cells.  Whole 
cell extracts were generated by lysing cells in PBS containing 1.5% DDM and a complete 
protease inhibitor cocktail.  Lysates from HEK293 cells and fibroblasts from control and SCO 
patient backgrounds were separated on a 12% SDS-PAGE gel.  The resultant membrane was 
subsequently blotted with anti-SCO1.  Blotting with anti-actin served as a loading control.   
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3.3.3 Co-immunoprecipitation of endogenous SCO1 from control and SCO patient 
mitochondria.   
To optimize quantitative pulldown of endogenous SCO1, co-immunoprecipitations were 
performed in the absence of crosslinker.  Purified SCO1 antibody was incubated with 
mitochondrial extracts at an antibody to protein ratio that was effective for co-
immunoprecipitation of SCO1-FLAG (1:7.5), and at an antibody to total protein ratio that was 4 
fold higher (4:7.5).  Protein bound to the antibody-bead complex was first eluted in 5% acetic 
acid, and then by boiling in sample loading buffer (Figure 3.8A). This analysis showed that 
incubation  with 5% acetic acid (E1) was sufficient to elute all of the bound SCO1, and that the 
1:7.5 ratio of antibody to protein was unable to quantitatively deplete SCO1 from the input 
fraction. To determine the minimal amount of antibody required for quantitative SCO1 
pulldown, co- immunoprecipitations were repeated with varying antibody to protein ratios.  
These analyses demonstrated that the majority of SCO1 was depleted from the input fraction 
using a ratio of 3:7.5 (Figure 3.8B), a result that was not affected by crosslinking (data not 
shown).  This ratio was therefore used for all future co-immunoprecipitation experiments. 
 
 
 
Figure 3.7: Immunoblot analysis of crosslinked mitochondrial extracts.  Mitochondria isolated 
from control and SCO1-2 patient fibroblasts were incubated with or without DSG.  Protein 
extracts were separated on a 4-20% SDS-PAGE gel, and the membrane was immunoblotted with 
affinity-purified SCO1 antibody. 
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To ensure that sufficient protein was present in the eluate to identify interacting partners, 
large-scale co-immunoprecipitations were conducted with crosslinked mitochondrial extracts 
isolated from control, SCO1-1, SCO1-2 and SCO2 patient fibroblasts.  Crosslinked mitochondrial 
extracts from control fibroblasts were also incubated with DynaBeads alone, which served as an 
internal, negative control.  Following elution with 5% acetic acid, a fraction of the eluate was 
analyzed by Western blotting to confirm the co-immunoprecipitation was successful, and that it 
contained higher order, crosslinked SCO1 adducts (Figure 3.9).  The remainder of the eluate 
(80%) was TCA precipitated, and sent for LC-MS analysis.   
   
 
 
Figure 3.8: Optimization of co-immunoprecipitation of endogenous SCO1.  (A) Endogenous 
SCO1 was co-immunoprecipated using either a ratio of antibody-bead complex to total 
mitochondrial protein of 1:7.5 or 4:7.5.  Beads were washed, and incubated sequentially in acetic 
acid (E1) and boiling sample loading buffer with reductant (E2).  Acetic acid elutions were TCA 
precipitated, the indicated percentage of each fraction was separated a 4-20% SDS-PAGE gel, 
and the membrane was then blotted with crude SCO1 antibody.  (B) Co-immunoprecipitations 
were performed as described in panel A, with the antibody-bead to protein ratio being increased 
as indicated.  Equal percentages (50%) of all samples were separated on a 4-20% SDS-PAGE 
and blotted with affinity-purified SCO1 antibody. 
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3.3.4 Mass spectrometric analysis of the eluates 
Mass spectrometric analysis of SCO1 eluates isolated from control and SCO patient cells 
identified 653 different proteins that were common to all samples. 
  
3.4 Prioritization of candidate interacting partners 
Mass spectrometric analysis of eluates from both the epitope-tagged and endogenous co-
immunoprecipitations of SCO1 produced large lists of potential interacting partners.  
Specifically, 436 and 653 unique proteins were identified in the FLAG-tagged and endogenous 
SCO1 co-immunoprecipitations.  There was therefore a pressing need to collate and refine these 
two datasets, to generate a prioritized list of candidate interactions worthy of further 
investigation.  Because of the potential confounding effects of using an overexpression system, 
candidate interacting partners identified by co-immunoprecipitating endogenous SCO1 were first 
considered.  To begin, proteins with a significant peptide count (>5) in the beads alone control 
 
 
Figure 3.9: Validation of SCO1 co-immunoprecipitation by Western blot analysis.  Crosslinked 
mitochondrial extracts from control fibroblasts were immunoprecipitated with affinity-purified 
SCO1 antibody.  The eluate was TCA precipitated, and a percentage of each fraction was 
separated on a 12% SDS-PAGE gel.  The resultant membrane was blotted with purified SCO1 
antibody, followed by an antibody which recognizes SD70, another mitochondrial protein that is 
associated with the inner membrane.   
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were removed from the list.  Proteins with annotated gene ontology functions related to 
immunity or  the  cytoskeleton were  then  discarded, as were those that are not contained within 
MitoCarta, a gold standard compendium of all known human mitochondrial proteins (Pagliarini 
et al., 2008).  This strategy collectively reduced the list of candidate interacting partners to a total 
of 157 proteins, which were then rank ordered based on the total number of peptide fragments 
identified for each protein.  Because there was still a significant number of potential interacting 
partners, the candidate interactions identified in the SCO1-FLAG co-immunoprecipitation were 
prioritized using the identical strategy.  This reduced the final list of potential interacting partners 
of SCO1-FLAG to 141, 85 of which were also identified by co-immunoprecipitation of the 
endogenous protein.   
 After collating the two datasets, SCO1 was the third ranked hit based on total number of 
peptides identified per protein (Table 3.1).  However, none of the top ranked proteins was an 
attractive candidate, given the curated literature describing their function (see Discussion, for 
more details).  Other proteins that were identified had fewer peptide fragments.  Many of these 
were known COX structural subunits or COX assembly factors, while others were metabolite 
transporters (Table 3.2).  Therefore, the focus of the remainder of my M.Sc. studies was to 
validate the observed physical interaction between SCO1 and COX20, a known COX assembly 
factor with an ill-defined role in holoenzyme biogenesis; and between SCO1 and SLC25A1 and 
SLC25A11, two metabolite transporters that may also be involved in trafficking copper across 
the inner mitochondrial membrane.   
 
3.5 Characterization of COX20, a COX assembly factor  
If SCO1 and COX20 function together during COX assembly, pathogenic mutations in 
SCO1 or SCO2 that interfere with COX assembly may affect the steady-state levels of COX20.  
Indeed, Western blot analysis showed a modest increase in the abundance of COX20 in SCO1-1 
and SCO2-9 patient cells (Figure 3.10).   
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Table 3.1: Proteins with highest peptide numbers identified in eluates of co-
immunoprecipitations of SCO1-FLAG (-FLAG) from HEK293 cells and SCO1 from control 
(Ctrl) fibroblasts.   
 
Peptides identified (#) Protein name 
-FLAG Ctrl  
16 66 Mitochondrial inner membrane protein (IMMT) 
14 40 Stomatin-like protein 2 (STOML2) 
42 31 SCO1  
1 30 Hexokinase-1 (HK1) 
6 29 NADH-ubiquinone oxidoreductase 75 kDa subunit (NDUFS1) 
10 29 Cytochrome b-c1 complex subunit 2 (UQCRC2) 
3 28 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, (NDUFS3) 
15 27 Elongation factor Tu (TUFM) 
12 26 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, (CHCHD3) 
16 25 Voltage-dependent anion-selective channel protein 2 (VDAC2)  
.   
Table 3.2: Rank ordered proteins in eluates of co-immunoprecipitations of SCO1-FLAG (-
FLAG) from HEK293 cells and SCO1 from control (Ctrl) fibroblasts that are known (A) and 
potential (B) interacting partners of SCO1. 
 
A 
Peptides identified (#) Protein name 
-FLAG Ctrl  
1 4 Cytochrome c oxidase subunit 4 (COX4) 
0 4 Cytochrome c oxidase subunit 5B (COX5B)  
2 2 Cytochrome c oxidase subunit 2 (COX II)  
 
B 
Peptides identified (#) Protein name 
-FLAG Ctrl  
7 20 Phosphate carrier protein (SLC25A3 or PIC2) 
7 15 Tricarboxylate transport protein (SLC25A1) 
2 9 Mitochondrial 2-oxoglutarate/malate carrier (SLC25A11) 
2 2 Cytochrome c oxidase protein 20 (COX20) 
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3.5.1 Validation of physical interaction between SCO1 and COX20 
To validate the observed interaction between SCO1 and COX20, I took advantage of a 
cell line generated by a collaborator (Dr. Antonio Barrientos, University of Miami).  More 
specifically, TALENs technology was used to knockout the COX20 gene in HEK293 cells, and 
FLAG-tagged  COX20  was  then stably overexpressed in one of the resultant knockout clones, 
to create  a  line  hereafter  named  KO-COX20  +  COX20-FLAG  (Bourens  et  al.,  2014).  
Consistent with the mass spectrometry data, SCO1 was co-purified by immunoprecipitation of 
COX20-FLAG from uncrosslinked mitochondria (Bourens et al., 2014).  The reciprocal 
immunoprecipitation with our SCO1 antibody also resulted in the specific pulldown of a small 
amount of FLAG-tagged COX20 (Figure 3.11).   
 
3.5.2 Effect of siRNA knockdown of COX20 on COX II abundance 
To better understand the functional significance of the physical interaction between 
COX20 and SCO1, COX20 was transiently knocked down in control and SCO patient 
fibroblasts.  Transfection of cells with BLOCK-iT Alexa scrambled siRNA served as an internal, 
negative, control.  Untreated and siRNA treated cells were harvested and a digitonized fraction 
was subsequently analyzed by Western blotting (Figure 3.12).  Treatment with either COX20 
siRNA1 or siRNA2 significantly reduced the abundance of COX20 in control and patient 
fibroblast lines, and modestly, but reproducibly, reduced the levels of COX II in SCO patient 
 
Figure 3.10:  Steady-state protein levels of COX20.  Control (C-1 and C-2) and SCO patient 
fibroblasts were permeabilized using digitonin to enrich the lysate for mitochondria.  Samples 
were separated using a 15% SDS-PAGE gel and blotted with the appropriate antibodies.  SDH70 
and Porin were used as mitochondrial loading controls.  The asterisk (*) indicates a background 
band observed with the COX20 antibody. 
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cells.  Because the abundance of COX II is a marker of holoenzyme content, this result provides 
genetic evidence that further supports an important role for an interaction between COX20 and 
SCO1 in COX assembly. 
 
 
Figure 3.11:  SCO1 interacts with epitope-tagged COX20.  Mitochondria isolated from the KO-
COX20 + COX20-FLAG cell line were lysed (IP) and incubated overnight with a SCO1 
antibody-bead conjugate.  Unbound extract (UB) was removed, and beads were washed three 
times (W) prior to boiling in sample loading buffer with reductant (E).  The washes were pooled, 
and a percentage of each fraction was separated on a 15% SDS-PAGE gel.  The blot was then 
probed with purified SCO1 and FLAG antibodies. 
 
 
 
 
Figure 3.12:  Knockdown of COX20 reduces COX II levels in SCO patient fibroblasts.  Control 
and patient fibroblasts were transfected with two separate siRNA constructs targeted to COX20 
for 9 days.  On day 9, cells were harvested and permeabilized using digitonin to enrich the lysate 
for mitochondria.  Samples were separated using SDS-PAGE and blotted with the appropriate 
antibodies.  SDH70 and Porin were used as loading controls. The asterisk (*) indicates a 
background band observed with the COX20 antibody. 
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3.6 Characterization of metabolite transporters SLC25A1 and SLC25A11 
If SLC25A1 or SLC25A11 physically interact with SCO1, their abundance may be 
affected in SCO patient cells that present with copper deficiencies.  However, Western blot 
analysis showed no change in SLC25A1 or SLC25A11 protein levels in patient fibroblasts 
(Figure 3.13).  
 
3.6.1 Validation of physical interactions 
In yeast, Pic2 was recently identified as the first copper transporter of the inner mitochondrial 
membrane (Vest et al., 2013).  It is unknown whether its human homologue, SCL25A3, fulfills a 
similar role in copper transport.  SLC25A3 was identified as potential interacting partner of 
SCO1, however no high-quality antibodies were available for further analysis.  Two other SLC 
family members, SLC25A1 and SLC25A11, were also identified as potential interacting partners 
of SCO1, and good quality antibodies raised against each of these proteins are commercially 
available.  Therefore, SCO1, SLC25A1, or SLC25A11 were purified with the appropriate 
primary antibody from uncrosslinked  mitochondria derived  from control fibroblasts.   Western 
blot analysis demonstrated that SLC25A1 and SLC25A11 were co-immunoprecipitated with 
SCO1 (Figure 3.14A).  Consistent with this observation, SCO1 was also found in the eluate  
 
 
Figure 3.13:  Steady-state protein levels of SLC25A1 and SLC25A11.  Control and SCO patient 
fibroblasts were permeabilized using digitonin to enrich the lysate for mitochondria.  Samples 
were separated using SDS-PAGE and blotted with the appropriate antibodies.  SDH70 and Porin 
were used as mitochondrial loading controls.   
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upon co-immunoprecipitation with either the SLC25A11 or SLC25A1 antibody (Figures 3.14B 
and 3.14C).  Membranes were blotted with antibodies against CORE1, a subunit of Complex III, 
as a control. 
 
Figure 3.14:  SCO1 interacts with SLC25A11 and SLC25A1 without the addition of chemical 
crosslinkers.  Mitochondria were isolated from control fibroblasts and subsequently lysed (IP).  
Lysate was then incubated with SCO1 (A), SLC25A11 (B), or SLC25A1 (C) antibodies 
conjugated to beads overnight.  Unbound extract (UB) was removed, and beads were washed 
three times (W) followed by elution in acetic acid (E1) and/or boiling in sample loading buffer 
with reductant (E2 or E).  Samples were separated by SDS-PAGE followed by blotting with the 
appropriate antibodies. 
 
52 
 
3.6.2 Effect of siRNA knockdown of SLC25A1 or SLC25A11 on COX II abundance  
Copper is required for the maturation of the CuA site of COX II and subsequent insertion 
of the protein into  the  assembling  holoenzyme.  Therefore,  if  interactions between  SCO1  and 
SLC25A1 or  SLC25A11 are involved in  copper  transport  across  the  inner  mitochondrial 
membrane and delivery of the metal ion to COX II, we reasoned that manipulating the 
expression of either metabolite transporter may affect COX II abundance.  HEK293 cells were 
stably transduced with cDNAs to overexpress SLC25A1 or SL25A11, and whole cell extracts 
were separated by SDS-PAGE.  While stable drug resistant cell lines were isolated, there was no 
discernible overexpression of either SLC25A1 or SLC25A11, even though there was a 
significant and reproducible decrease in COX II steady-state-levels (Figure 3.15A and 3.15B).  
To determine whether the reduced levels of COX II were simply a consequence of 
overexpressing an inner mitochondrial membrane protein, extracts were also prepared from 
HEK293 cells overexpressing SCO1 or SCO2.  The abundance of COX II was only affected in 
HEK293 cells overexpressing the metabolite transporters (Figure 3.15C).   
 
Figure 3.15: Overexpression of SLC25A1 or SLC25A11 affects COX II levels.  Retroviral 
vectors containing SLC25A1 (A) or SLC25A11 (B) were transduced into HEK293 cells.  Whole 
cell extracts were separated using SDS-PAGE and blotted with appropriate antibodies.  (C) 
Retroviral vectors containing SLC25A1, SLC25A11, SCO1 or SCO2 were transduced into 
HEK293 cells.  Actin was used as a loading control. 
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To further investigate a role for SLC25A1 or SLC25A11 in COX assembly, their 
abundance was transiently knocked down in control and SCO patient fibroblasts using specific 
siRNAs.  After 8 days, untreated or siRNA treated fibroblasts were harvested and whole cell 
extracts were analyzed by Western blotting.  Significant knockdown of SLC25A11 was observed 
in all fibroblast lines transiently transfected with any of 3 different siRNA constructs, with 
siRNA1 having the most modest effect on SLC25A11 abundance (Figure 3.16A).  COX II 
abundance was reduced in control (C-1 and C-2) and SCO1-2 patient fibroblasts in which the 
steady-state levels of SLC25A11 were not immunologically detectable.  In contrast, the steady-
state levels of COX II in SCO2 patient fibroblasts were independent of SLC25A11 abundance.  
Successful knockdown of SLC25A1 was also observed in all fibroblast lines; however, siRNA1 
was the least effective of the three siRNAs (3.16B).  Although SLC25A1 knockdown did not 
affect COX II abundance in control (C-1 and C-2) and SCO1-1 fibroblasts, the steady-state levels 
of COX II were increased in SCO1-1 and SCO2-9 fibroblasts in which SLC25A1 abundance was 
significantly reduced but remained immunologically detectable.  However, the potential 
relationship between SLC25A1 and COX II in these genetic backgrounds appears to be 
complicated, because more efficient knockdown of SLC25A1 led to a complete loss of 
immunologically detectable COX II.  To further evaluate whether the effect of knocking down 
SLC25A1 or SLC25A11 was specific to COX or also affected the abundance of other complexes 
of oxidative phosphorylation, extracts from C-1 and SCO1-2 fibroblasts transfected with siRNA 
were blotted with antibodies against subunits from the other three complexes of the electron 
transport chain (Figure 3.16C).  These analyses demonstrated that the abundance of Complexes I, 
II and III is unaffected when either SLC25A1 or SLC25A11 are knocked down. 
  
 
Figure 3.16: Knockdown of SLC25A11 and SLC25A1 in control and SCO patient fibroblasts.  Control (C-1 and C-2) and SCO patient 
fibroblasts were transfected with three siRNA constructs targeted to SLC25A11 or SLC25A1.  On day 8, cells were harvested and 
lysate was separated on SDS-PAGE gels.  Membranes were subsequently blotted to verify knockdown of SLC25A11 (A) or SLC25A1 
(B) with the indicated primary antibodies.  Tubulin and Porin were used as cytoplasmic and mitochondrial loading controls, 
respectively. The asterisk denotes residual chemiluminescence from the SLC25A1 antibody. Separate membranes were blotted with 
antibodies against structural subunits from other OXPHOS complexes (C). 
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4 DISCUSSION 
4.1 Interpretation of hit list of potential interacting partners of SCO1.   
A greater understanding of how SCO1 metallates COX II or contributes to the 
mitochondrial regulation of cellular copper homeostasis requires the identification of its 
interacting partners.  Physical interaction studies with metallochaperones are challenged by the 
highly transient nature of their interactions, and the fact that these interactions are typically 
stabilized by weak, non-covalent bonds (Chen et al., 2013).  To address these challenges, I used 
a chemical crosslinking approach to stabilize interactions between SCO1 and its protein partners.  
Overexpressed SCO1-FLAG or endogenous SCO1 were subsequently immunoprecipitated from 
mitochondria, and co-eluted proteins were identified by mass spectrometry.  As expected, the list 
of potential interacting partners was large, and the number of non-specific hits was significant.  
Structural proteins and subunits from other oxidative phosphorylation complexes were enriched. 
However, this was not surprising because the COX holoenzyme forms large super-structures 
termed respirasomes that are comprised of many of the enzyme complexes of oxidative 
phosphorylation (Shoubridge, 2012).  Therefore, the close proximity of these enzyme complexes 
to the machinery that promotes their assembly could potentiate their crosslinking to SCO1, even 
though evidence ascribing any functional significance to these interactions is currently lacking.  
Several mitochondrial proteases were also identified in the eluate fractions of both SCO1 and 
SCO1-FLAG immunoprecipitations.  This argues that enrichment for proteases is not simply due 
to the overexpression of an epitope-tagged variant, something that has been observed in previous 
studies that have employed co-immunoprecipitation as an experimental strategy (Stiburek et al., 
2012).  Several structural subunits of the COX holoenzyme were also identified in my co-
immunoprecipitations, including the catalytic core subunit COX II and two of the protein 
constituents of the S2 assembly intermediate, COX IV and COX Va (Fontanesi et al., 2008; 
Tsukihara et al., 1995; Tsukihara et al., 1996).  The co-purification of these structural subunits 
with SCO1 further supports the idea that SCO1 is essential for the maturation of COX II at the 
S2 stage of holoenzyme assembly (Leary et al., 2004; Nijtmans et al., 1998; Shoubridge, 2001).   
COX I and SCO2 are two proteins that I expected to co-elute with SCO1 that were not 
detected in the mass spectrometric analyses.  COX I is the core catalytic subunit of COX that 
seeds holoenzyme assembly and, along with COX IV and COX Va, forms the S2 assembly 
intermediate (Fontanesi et al., 2008).  COX I is a very hydrophobic protein, and its hydrophobic 
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nature is believed to have prevented lateral gene transfer to the nucleus (Gray et al., 1999).  
Perhaps the physico-chemical properties of COX I promoted its aggregation and therefore 
precipitation, either during purification of the immune complex or subsequent processing of the 
sample (Gray et al., 1999; Tsukihara et al., 1996).  SCO2 was also not identified as a potential 
interacting partner of SCO1, even though significant molecular genetic evidence argues that each 
protein fulfills an essential, complementary function at the S2 stage of COX assembly (Leary et 
al., 2004; Leary et al., 2009).  SCO1 and SCO2 are present as homodimers in fibroblasts, and 
COX assembly is only affected by overexpressing a given SCO protein in the reciprocal SCO 
patient background (e.g.  SCO1 overexpression in SCO2 patient cells) (Leary et al., 2004).  The 
inability of overexpressed SCO1 or SCO2 to reduce COX activity in control cells argues that 
only a small percentage of the SCO1 protein pool interacts with the SCO2 protein pool.  Thus, 
capturing a physical interaction between SCO proteins that is detectable by mass spectrometry 
may require that immunoprecipitations be conducted following experimental manipulations that 
promote COX assembly (e.g.  pulse-chase labeling) (Leary et al., 2009).  It is important to note, 
however, that there is no evidence of a direct physical interaction between human SCO1 and 
SCO2 in the literature.  This raises the possibility that SCO proteins act sequentially to mature 
COX II by interacting with the polypeptide directly or with one or more of the COX assembly 
factors that chaperones COX II during its maturation.   
My co-immunoprecipitation experiments also did not reveal any obvious candidates that 
may be involved in the generation or transduction of a SCO1-dependent mitochondrial redox 
signal that regulates cellular copper homeostasis.  Recently, functional genetic experiments 
identified COX19 as a critical component of this signal transduction pathway (Leary et al., 
2013b).  The fact that COX19 was not present in the eluate suggests that it may not interact with 
SCO1 directly, or that it does but the physical interaction was not detected due to technical 
limitations of the experiment.  I favour the latter possibility, because the resultant hit list from the 
mass spectrometric analysis did not contain any soluble, IMS localized proteins, even though it is 
well established that COX17 transfers copper to SCO1 via ligand exchange (Banci et al., 2007b; 
Banci et al., 2008; Cobine et al., 2006b).  My inability to detect interactions between SCO1 and 
IMS proteins like COX17 and COX19 may be explained by the rapid on/off kinetics of their 
interactions, which would make them more difficult to crosslink chemically.  Efficient 
crosslinking of membrane proteins and IMS factors may also have been challenged by the fact 
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that this latter group of proteins moves in three dimensions.  Alternatively, the OMM may have 
been damaged during mitochondrial isolation, which would have significantly reduced the 
abundance of IMS proteins available for subsequent crosslinking reactions.   
Mass spectrometric analysis of eluates from FLAG-tagged and endogenous SCO1 co-
immunoprecipitations provided lists of candidate interacting partners that were too large and 
therefore made an unbiased validation approach impractical.  As such, a set of rationalized 
criteria was used to generate a prioritized list of candidate interacting partners from the two 
datasets.  Proteins with annotated gene ontology functions related to the cytoskeleton or immune-
related processes were discarded, because SCO1 has no role in either of these broad biological 
processes.  The MitoCarta database was then used to remove any remaining proteins that are not 
localized to the mitochondrion, because SCO1 is tethered to the IMM and therefore can only 
physically interact with other mitochondrial proteins.  The resultant list contained 85 proteins 
that were then rank ordered based on the total number of identified peptide fragments.  SCO1 
was the third highest ranked protein on the final list, with two other proteins having higher 
peptide counts; IMMT and STOML2.  IMMT is involved in mitochondrial cristae remodeling, 
while STOML2 interacts with Complexes I and II is thought to be involved in mitochondrial 
biogenesis (Christie et al., 2011; John et al., 2005).  Other identified proteins with high peptide 
counts included structural subunits of oxidative phosphorylation complexes (NDUFS1, 
NDUFS3, UQCRC2), a protein involved in maintaining mitochondrial cristae integrity 
(CHCHD3), an OMM pore protein (VDAC2) (Yu et al., 1995; Darshi et al., 2011; Iwata et al., 
1998; Brandt, 2006), and a mitochondrial translation factor (TUFM) (Valente et al., 2007).  
However, none of these proteins represented strong candidates worthy of further investigation, 
because a clear connection between their function and that of SCO1 is currently lacking.  
Therefore, in the interest of time and money, I chose to validate and characterize interactions 
between SCO1 and three candidates with lower peptide counts; COX20, a known COX assembly 
factor with an ill-defined role in holoenzyme biogenesis; and, SLC25A1 and/or SLC25A11, two 
transporters that may be involved in translocating copper across the IMM.  
 
4.2 Significance of the interaction between SCO1 and COX20 to COX assembly  
 My M.Sc. project was part of a larger collaborative effort that investigated the 
significance of the physical interaction between SCO1 and COX20 to COX assembly (Bourens 
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et al, submitted).  My contribution to this research was to establish that SCO1 co-
immunoprecipitated COX20, and to evaluate the effect of COX20 knockdown on COX assembly 
in control, SCO1 and SCO2 patient fibroblasts.  I was able to show that both in the absence and 
presence of crosslinkers, a small amount of COX20 co-eluted with SCO1.  I further 
demonstrated that siRNA knockdown of COX20 reduced the steady-state levels of COX II, a 
direct proxy of COX content, in SCO1 and SCO2 patient fibroblasts, but not in control fibroblast 
lines.  Taken together, these data are consistent with a model whereby SCO1 physically interacts 
with COX20, and that this interaction is critical to COX assembly likely at the S2 stage of 
holoenzyme biogenesis, because this assembly intermediate accumulates in SCO patient 
fibroblasts and in COX20 knockdown or knockout cells (Bourens et al, submitted). 
 While these findings advance our mechanistic understanding of COX assembly, the 
specific function of human COX20 remains poorly understood.  In contrast, the yeast homologue 
has been studied extensively.  Cox20 interacts with Cox2 following Oxa1-mediated translocation 
of its N-terminal domain across the IMM, and presents Cox2 to the IMP peptidase complex to 
facilitate the proteolytic removal of its N-terminal presequence (He and Fox, 1997; Hell et al., 
1998; Hell et al., 2000).  Cox20 then collaborates with Cox18 to promote the subsequent export 
of the C-terminal domain of Cox2 (Funes et al., 2004; Saracco and Fox, 2002).  Existing data 
suggest that Oxa1 does not physically interact with Cox20, and that Cox2 is required to stabilize 
the interaction between Cox18 and Cox20 (Elliott et al., 2012).  The mechanisms that govern the 
insertion of newly synthesized COX II into the IMM and facilitate subsequent maturation of the 
polypeptide in humans are not well understood.  Although human cells express homologues of 
yeast Cox18, Cox20 and Oxa1 (Haque et al., 2010; Sacconi et al., 2005; Szklarczyk et al., 2013), 
their respective roles in COX assembly remain poorly defined.  Interestingly, OXA1L was 
identified by mass spectrometric analysis of chemically crosslinked eluates from SCO1 co-
immunoprecipitations.  However, it is unlikely that the observed interaction directly relates to 
COX assembly, as SCO1 interact with COX II after the protein has been translocated into the 
IMM by OXA1L.  Because OXA1L also has a role in targeting newly imported mitochondrial 
proteins to the IMM (Hell et al., 2001), it is possible that co-elution of OXA1L with SCO1 
reflects an interaction between the two proteins that is critical to insertion of SCO1 into the lipid 
bilayer. 
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Yeast Cox20 is also thought to act as a chaperone to stabilize Cox2 during its maturation 
(Elliott et al., 2012).  Consistent with the idea that this chaperone function is conserved in higher 
eukaryotes and relates to the maturation of the CuA site of COX II, my Western blot analysis 
showed that the abundance of COX20 is modestly increased in SCO1 and SCO2 patient 
fibroblasts.  This suggests that cells attempt to address the loss of SCO1 or SCO2 function by 
increasing the steady-state levels of COX20.  While highly speculative, one could test this 
hypothesis by determining whether overexpression of COX20 rescues the COX deficiency in 
SCO patient cells.  I would also analyze the COX20 abundance in patient cells with isolated 
COX deficiencies caused by pathogenic mutations in other COX assembly factors such as 
COX10 or SURF1 (Antonicka et al., 2003; Lee et al., 2012; Stiburek et al., 2005; Valnot et al., 
2000a).  If COX20 abundance is unchanged, this would further support the idea that SCO patient 
cells increase the steady-state levels of COX20 in an attempt to rescue the COX assembly defect. 
Unlike other COX assembly factors, human COX20 does not appear to be essential for 
holoenzyme biogenesis.  HEK293T cells in which COX20 is knocked out still have roughly 25% 
of the COX content of the parental line (Bourens et al, submitted).  Moreover, a pathogenic T52P 
mutation in COX20 severely impairs COX assembly, particularly in striated muscle, but is not 
associated with early onset fatal clinical outcomes (Doss et al., 2013; Szklarczyk et al., 2013).  
However, Western blot analysis demonstrated that COX20 patient fibroblasts express low, but 
detectable levels of the T52P mutant (Szklarczyk et al., 2013).  This suggests that the T52P 
substitution does not abolish COX20 function, and that sufficient residual function remains to 
support COX assembly.  Future studies of other COX20 pedigrees will be required to determine 
the importance of COX20 function to COX assembly in different cell types (Szklarczyk et al., 
2013), and a full understanding of COX20 function awaits the identification of all factors that are 
required to stabilize COX II and metallate its CuA site.   
 
4.3 Characterizing the potential roles of SCL25A1 and/or SLC25A11 in mitochondrial 
copper transport 
 The mitochondrial matrix contains a labile pool of copper that can be accessed for 
metallation of Cox1 and Cox2 during COX assembly (Cobine et al., 2006a).  In humans, the 
components involved in the regulated trafficking of copper ions to, within and from 
mitochondria remain unknown.  My project provided evidence that two IMM transporters, 
 60 
 
SLC25A1 and SLC25A11, interact with SCO1, and that these interactions are directly relevant to 
COX assembly.  Knockdown of either transporter reduced COX II levels in SCO1 and SCO2 
patient fibroblasts, while knockdown of SLC25A11 also lowered COX II abundance in control 
fibroblasts.   Why control cell lines transduced with a SLC25A1 or SLC25A11 cDNA also exhibit 
a reduction in COX II abundance, even though by Western blot analysis neither transporter 
appeared to be overexpressed, remains unclear.  However, the fact that the steady-state levels of 
COX II were reduced in control fibroblasts upon knockdown of SLC25A11 suggests that it plays 
a more prominent role than SLC25A1 in COX assembly.  COX assembly defects in cells with 
attenuated expression of either transporter may reflect a compromised ability to traffic copper 
across the IMM for its eventual loading by SCO1 into COX II. It will be important to directly 
address this possibility by quantifying the effect of knocking down each protein in isolation and 
together on total cellular and mitochondrial copper content.   
 The majority of mitochondrial copper is bound by a soluble, anionic complex defined as 
the copper ligand (CuL) (Cobine et al., 2004).  Data from previous studies suggest that the CuL 
complex may resemble a metabolite or nucleotide (Yang et al., 2005).  Therefore, copper 
transport across the IMM may rely on one or more mitochondrial metabolite transporters.  The 
solute carrier 25 (SLC25) family of proteins consists of nuclear-encoded transporters embedded 
in the IMM, and in unique cases other organellar membranes.  These carriers are highly 
conserved, and are responsible for the transport of metabolites, nucleotides, and co-factors across 
membranes.  SLC25 transporters typically have primary substrates, but are also able to transport 
other related compounds, albeit with lower affinity (Palmieri, 2004; Palmieri et al., 2011; 
Palmieri, 2013; Picault et al., 2004).  This provides overlapping substrate specificity among 
family members and redundant pathways for transport of a given molecule.  Consistent with 
these observations, a phosphate carrier of the IMM, Pic2, was recently identified as the first 
mitochondrial copper transporter in yeast (Vest et al., 2013).  A role for the human homologue of 
Pic2, SLC25A3, in copper transport has not yet been identified, and although human SLC25A3 
co-immunoprecipitated with SCO1 in chemically crosslinked eluates, we could not find any 
commercial antibodies of suitable quality to further investigate the potential significance of this 
interaction.  In contrast, robust reagents were available for SLC25A1 and SLC25A11 and the 
importance of these proteins to SCO1 function was therefore further characterized.  SLC25A1 
predominantly catalyzes the import of malate while simultaneously exporting citrate from the 
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matrix (Capobianco et al., 1995; Palmieri et al., 1972b; Palmieri, 2013).  Patients with 
pathogenic mutations in SLC25A1 present with severe neonatal epileptic encephalopathy.  This 
condition often results in early death, and is associated with increased levels of several Krebs 
cycle intermediates and elevated serum levels of 2-hydroxyglutarate (Nota et al., 2013).  
SLC25A11 has been shown to transport 2-oxoglutarate into the matrix, in exchange for malate or 
other dicarboxylic acids (Monne et al., 2013; Palmieri et al., 1972a; Robinson and Chappell, 
1967). 
Functional redundancy may explain the difficulty the scientific community has had with 
respect to the identification of IMM copper transporters.  In fact, mitochondrial iron transport is 
known to rely on multiple SLC family members who, although they exhibit varying degrees of 
specificity for iron transport, are nonetheless able to functionally complement for the loss of each 
other’s function (Gordon et al., 2006; Muhlenhoff et al., 2003; Yoon et al., 2011).  The potential 
roles of SLC25A1 and SLC25A11 in mitochondrial copper trafficking require further 
experimentation.  Both SLC25A1 and SLC25A11 are bi-directional antiport transporters, 
suggesting they could traffic copper to or from the matrix (Palmieri, 2013).  However, because 
SCO1 does not have a known role in the regulated trafficking of copper to the matrix, I favour 
the idea that one or both of these transporters exports copper to the IMS.  Multiple lines of 
evidence support a model whereby SCO1 receives copper from COX17 (Banci et al., 2007b; 
Banci et al., 2008; Cobine et al., 2006b).  Given that free copper is essentially undetectable in the 
cell (Rae et al., 1999), and that free copper within the IMS would be predicted to potentiate 
Fenton chemistry, one possibility is that SLC25A1 and/or SLC25A11 supply copper to IMS 
metallochaperones like COX17 for its subsequent delivery to SCO1.  The fact that I observed a 
physical interaction between SCO1 and both transporters, however, suggests that this may 
involve the formation of a ternary complex containing SLC25A1 or SLC25A11, COX17 and 
SCO1.  A second, mutually exclusive possibility is that SCO1 interacts with SLC25A1 and/or 
SLC25A11 to inhibit their copper transport activity, although this seems less likely because 
SCO1 patient fibroblasts maintain wild-type levels of mitochondrial copper even in the face of a 
severe copper deficiency at the cellular level (Dodani et al., 2011).  Further mechanistic insight 
into the trafficking of copper across the IMM will require the identification and functional 
characterization of most, if not all, relevant transporters.   
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4.4 Future directions 
 In addition to identifying and confirming the physical interaction between SCO1 and 
COX20, SLC25A1 and SLC25A11, my M.Sc. thesis work identified a substantial number of 
additional proteins that may also interact with SCO1 and be worthy of further investigation.  The 
fact that the stability of newly synthesized COX II is significantly affected by mutations in SCO1 
and SCO2 (Leary et al., 2009) suggests that both SCO proteins may affect COX II stability by 
interacting with one or more mitochondrial proteases.  Interestingly, immunoprecipitation of 
SCO1-FLAG and endogenous SCO1 identified two proteases as potential interacting partners of 
SCO1; ATPase family member 3-Like 2 (AFG3L2) and YME1L.  Both proteases are structurally 
similar and anchored to the IMM by either one or two transmembrane domains (Gerdes et al., 
2012; Rugarli and Langer, 2012).  The catalytic region of YME1L resides in the IMS and 
reductions in its abundance leads to accumulation of non-assembled respiratory chain subunits 
(Leonhard et al., 1996; Stiburek et al., 2012).  The catalytic domains of AFG3L2 face the matrix 
side of the IMM (Gerdes et al., 2012; Lee et al., 2011), and patients with loss of function 
mutations in AFG3L2 present with neurodegenerative disorders associated with defective 
mitochondrial quality control (Maltecca et al., 2008).  Therefore, while perturbed function of 
YME1L or AFG3L2 would exert pleiotropic effects on the expression of structural subunits of 
the complexes of oxidative phosphorylation, their interaction with SCO1 is worth further 
pursuing because they may act to degrade COX II that is not fully matured and inserted into the 
assembling holoenzyme.  Another potential interacting partner of SCO1 of interest was 
LRPPRC, a post-transcriptional regulatory factor that stabilizes mt-mRNA transcripts, including 
COX I, COX II and COX III (Cooper et al., 2006; Mootha et al., 2002; Sasarman et al., 2010).  
Mouse embryotic fibroblasts lacking LRPPRC exhibit a severe COX deficiency and slight 
decreases in the abundance of other oxidative phosphorylation complexes that contain mtDNA-
encoded subunits (Xu et al., 2012).  Because LRPPRC is localized to the matrix, it would 
interact with the soluble N-terminal tail of SCO1 that is also localized to that mitochondrial 
compartment.  I believe that such an interaction would serve to efficiently couple COX II 
translation with the subsequent maturation of the polypeptide.   
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